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Abstract 
Current research in pharmaceutical development commonly utilizes a profusion of 
methods in molecular modeling in order to probe intricate biological problems. Many original 
and promising compounds have been identified and developed by integrating experimental and 
computational methods. Structural biology utilizes many different research techniques including 
x-ray crystallography, NMR, and electron microscopy in order to develop molecular models of 
macromolecules that are of biological interest. Such techniques can be used in conjunction with 
molecular docking, which utilizes those molecular models in order to target macromolecules of 
therapeutic interest by computationally analyzing the conformations adopted by ligands upon 
interaction with a desired binding site and estimating the free energy of binding. This technique 
allows for the screening of millions of compounds with great variety in terms of structure and 
chemotype. The initial hits of such drug discovery efforts generally consist of low affinity small 
molecules, but by developing complex structures of these compounds with the macromolecular 
target they can be optimized through the addition of functional groups and enlarging the 
compound structure in order to take advantage of the chemical space surrounding the inhibitor 
within the binding site, which leads to higher affinity compounds. This is the process of a 
structure based drug design effort and the work herein utilizes this process in order to develop 
and optimize small molecule inhibitors that offer the potential to be utilized in battling bacterial 
resistance to current antibiotics and preventing the metastasis of different cancers. 
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The first project seeks to target the lipid A biosynthetic pathway which is a highly 
conserved biochemical process seen in all Gram-negative bacterial cells and has shown to be 
essential for the growth and survival of Pseudomonas aeruginosa. Two of the enzymes involved 
in this biochemical pathway, LpxA and LpxD, display high structural similarity and catalyze 
highly similar reactions which offers the unique chance to potentially develop dual activity 
inhibitors that bind to both enzymes. Such small molecules should lead to an increase in 
inhibitory effects and lower the possibility of mutational resistance to develop against such 
activity. By developing x-ray crystallographic structures of the LpxA and LpxD enzymes we 
were able to use molecular docking to develop several initial hit compounds that bind to the 
active sites of both these proteins. The binding affinity for these compounds was determined 
using surface plasmon resonance and complex structures of the compounds with LpxA and 
LpxD were developed. These structures revealed a previously undetermined magnesium at the 
core of the LpxD trimer which may have biological relevance to the structure of the protein. 
Additionally, one of the inhibitors displayed allosteric effects upon binding to LpxD by inducing 
conformational changes in the C-terminal alpha-helical domain of the protein, which is 
responsible for forming substantial contacts with acyl carrier protein (ACP), a protein that 
functions by depositing the necessary catalytic substrate within the active site of LpxD. 
The second project also focused on targeting bacterial resistance in Pseudomonas 
aeruginosa but wanted to exploit the bacteria’s required functioning of its PBP3 enzyme for 
growth. PBP3 is a penicillin binding protein, enzymes involved in the catalytic formation of the 
bacterial cell wall. However, rather than developing new inhibitors with this project we sought to 
figure out why a known antibiotic, temocillin, displays broad spectrum activity against most 
resistant strains of bacteria but is limited when it comes to the ability to combat Pseudomonas 
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aeruginosa infections. We did so by analyzing how the 6-α-methoxy group on the compound’s β-
lactam ring influences the ability to bind to PBP3. Furthermore, we wanted to analyze the 
mechanism behind temocillin’s ability to counter antibiotic resistance. Looking at the influence 
of the 6-α-methoxy group involved looking at the binding kinetics of temocillin and ticarcillin (a 
parent compound of temocillin which varies structurally only in missing that 6-α-methoxy 
group) through fluorescence polarization assays, along with thermal shift assays, and the 
development of complex crystal structures between PBP3 and both compounds. In order to 
determine the mechanism behind temocillin’s ability to counter bacterial resistance we 
developed a complex structure of temocillin with CTX-M-14, a β-lactamase enzyme which is 
responsible for the catalytic degradation of many known antibiotic compounds. These studies 
will allow for the ability to improve and possibly develop new broad spectrum β-lactamase 
inhibitors and also hopefully lead to the development of new therapeutics that target clinically 
significant antibiotic resistant strains of Pseudomonas aeruginosa. 
The final project sought to develop small molecule inhibitors that targeted the CCR7 
signaling axis by targeting the protein-protein interfaces (PPIs) of the receptors cognate 
chemokines, CCL19 and CCL21. Both of these signaling proteins induce their effects by binding 
to the CCR7 receptor, which induces signaling cascades that result in cell motility and thus plays 
an important role in the trafficking of immune cells from the bloodstream into the lymphatic 
system. This signaling axis gets hijacked by cancer cells and plays a role in supporting tumor 
growth, angiogenesis, and metastasis of various cancers. Uniquely, sulfation of the N-terminal 
tyrosine residues of the CCR7 receptor plays a critical role in the binding of the chemokines by 
imparting large amounts of affinity for the interaction. The recognition sites for these sulfated 
tyrosines on the chemokines are highly conserved across this family of proteins and make for 
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ideal hot spots in the development of small molecule inhibitors to prevent these protein-protein 
interactions. In order to identify these recognition sites we used NMR perturbation assays to 
outline the binding pockets on the protein structure. We then developed x-ray crystallographic 
structures to utilize in molecular docking studies that screened for compounds that would bind to 
these surfaces. Further NMR perturbation assays were used to determine the binding constants of 
our selected compounds from the molecular docking experiments. The compounds developed by 
our efforts represent the first CCL21-specific inhibitors and support the hypothesis that the 
conserved sulfotyrosine recognition sites found on the chemokine family make for good small 
molecule drug targets in an effort to develop inhibitors that target these various signaling axes. 
Additionally, our crystal structures of these chemokines shed light on various structural 
mechanisms that play a role in these molecules ability to bind to their target receptor and give 
further insight into a basic understanding of potential regulatory mechanisms for altering their 
signaling. 
1 
Chapter 1: 
Introduction 
1.1 Bacterial Resistance to Antibiotic Treatments 
In the United States alone, 2 million people annually develop severe bacterial infections 
that are resistant to one or more antibiotics currently used to treat that infection. Out of those 2 
million people, 23,000 cases prove to be fatal as a direct result of their resistant infection.1 In 
addition to the risk of mortality, these incidents of infection result in huge financial and 
economic costs as well. Each case of antibiotic resistant bacterial infection adds an estimated 
$1,383 to the cost of treating a patient, which amounted to over $2 billion in added costs in the 
year 2014.3 This figure is double the amount spent in treating such infections in 2002, which can 
be seen when comparing the incidents of resistant infections between these years. While the 
number of bacterial infections remained relatively similar (13.5 million in 2002 and 14.3 million 
in 2014), the percentage of these infections that were resistant to antibiotic treatment went from 
just over five percent in 2002 (700,000 infections) to eleven percent in 2014 (1.6 million 
infections).3 The reason behind the spike in these types infections is multifactorial. One of the 
factors is the lack of novel antibiotic research, which has seen no new developments since 
carbapenems and fluoroquinolones were first introduced in the 1980s.4,5 The number of approved 
novel antibiotic treatments has been steadily decreasing each decade since the 1980s when over 
30 new therapeutics were released for use, dropping to just a little over 20 in the 1990s, and 
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under 10 between 2000 and 2012.1 The reason for the lack of innovation is that financial 
investment into research and development of new antibacterial medications is viewed by the 
pharmaceutical industry to not be a worthwhile endeavor.6 The lack of financial viability for 
developing new antibacterial medications has been supported by economic research that 
indicated the average net value of a novel antibiotic drug for a company is significantly less than 
that of the value of developing pharmaceuticals for chronic diseases.7 It isn’t just a lack of new 
drugs though that is causing this spike in untreatable infections; it is also due to the enormous 
and irresponsible overuse of antibiotics, which has been shown to be the major driving force 
behind the development of resistant strains.1,8 Small epidemiological studies in hospitals have 
identified a direct correlation between antibiotic use and increased prevalence for bacterial 
resistance amongst the patients.9 Part of this overuse problem is the result of inappropriate 
prescriptions by doctors, as shown by studies where medical practitioners’ choice of antibiotic, 
length of antibiotic treatment, or antibiotic indications were incorrect 30%-50% of the time.1,10 
These misdiagnoses can frequently lead to sub-inhibitory concentrations of the antibacterial in 
the patient’s bloodstream and this results in the introduction of alternative forms of mutagenesis, 
genetic expression, and horizontal gene transfer; all of which induce and propagate antibiotic 
resistance.11 Another major contributing factor to rise in rates of antibiotic resistance is the 
administration of antimicrobial agents to livestock, where they are used in prophylactic treatment 
of the animals and also as growth promoters.12 It is estimated that as much as 80% of the 
antibiotics sold in the United States are used to treat livestock.5 These antibiotics and the 
resistant bacteria found in the animals, as a result of their prophylactic treatment with the 
antibiotics, are then transferred to humans via the consumption of these animals and their 
byproducts.6,13 This combination of increased rates for development of antibiotic resistance and 
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lack of new innovation for drugs combatting these resistant strains of infection is poised to 
become a major health crisis unless money is invested into research to counteract resistance 
immediately. 
1.2 Cancer and Metastasis 
 Cancer is the second leading cause of death worldwide and continues to elude a cure.14 
This is largely because cancer is actually an extensive group of diseases with great degrees in 
variability with regards to the specific mechanisms of cellular deregulation by which they 
occur.15 In broad terms, all cancers are the result of mutations within the regulatory genes 
responsible for cell proliferation and apoptosis, which causes normal cell functioning to cease 
and continual cell replication to occur in conjunction with a blocking of proliferative inhibition 
and auto-apoptosis.16 As the tumor grows it may also spread to different areas of the body, and 
this spread is the cause of 90% of cancer related deaths.17 Metastatic cancers are significantly 
more difficult to get rid of due to the need to remove as many of the malignant cells throughout 
the body in order to enter remission and prevent recurrence of tumor formation. This along with 
the increased risk of complications caused by the spread of cancer cells can often limit treatment 
options.18  
Globally, there were a total of 17.2 million cases of cancer in 2016 and it caused a total of 
8.9 million deaths that same year. This number has continued to rise as the estimated number of 
deaths caused by cancer in 2018 was put at 9.6 million.15,19 In 2016 alone, cancer caused a loss 
of 213.2 million disability-adjusted life-years worldwide (the sum of years lived with disability 
and the years of life lost as a the result of a disease), which is a prevalent measure of the burden 
of cancer.19 The economic burden of cancer is also large; in 2015 the total annual medical costs 
caused by these diseases in the United States alone was $80.2 billion.20 The estimated cost 
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worldwide of cancer treatment in 2010 was $1.16 trillion dollars and as incidence rates rise (28% 
increase from 2006 to 2016) this number is sure to continue growing.15,19  
1.3 Structure-Based Drug Design 
Since the 1960s when the world saw the development of the first protein structures solved 
using x-ray crystallography, structural data has been used to help design more effective 
pharmaceuticals in an effort to more specifically target the pathways known to be involved with 
various disease states.21,22 These pioneering efforts to understand protein folding, the evolution 
of molecules, and the relationship between the structure and function of these proteins also led to 
the structural identification of many potential binding sites for the development of various 
inhibitors, and laid the essential groundwork for the now pullulating field of structure-based drug 
design (SBDD).21-24 There are many reasons why SBDD has grown so rapidly over the past few 
decades, but it is primarily due to the exponential improvement of the all the research techniques 
used in the implementation of SBDD research. Perhaps the most evident of these improvements 
can be seen in the three main techniques used for the development of structural models: (1) x-ray 
crystallography with now widely available access to high intensity x-ray sources and highly 
sensitive detectors capable of sub-angstrom resolution detection 25 (2) nuclear magnetic 
resonance (NMR) with improvements to sample preparation and access to high powered NMR 
spectrometers26 (3) cryogenic electron microscopy (cryo-EM) that has also seen vast 
improvements to sample preparation techniques, along with increased power and stability of the 
electron gun and higher sensitivity of detectors in the electron microscopes as well.27,28 These 
advances have resulted in a massive surge of structure depositions into the Protein Data Bank, 
with nearly 150,000 structures deposited to date and over half of those have been deposited in 
the past eight years.29 The improvement of these structures quality and the massive increase in 
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total number of structures has greatly helped increase the accuracy of virtual screening by 
providing much more precise and accurate data and in greater amounts, thus allowing for 
significant improvements to be made to in silico algorithms for predicting where and how 
compounds will bind to desired targets.30-32 Additionally, the exponential increase seen in 
availability of computing power has also allowed for more accurate prediction of compound 
binding with little sacrifice to speed of the virtual screen, due to less need for approximations to 
be made in the docking parameters for the sake of time efficiency.31,33 This acceleration of 
computing speed has also helped increase the speed of the overall process of finding successful 
lead candidates, along with the rapid growth of virtual compound libraries which allow for far 
greater chemical sampling than ever before.34,35 
  The process of SBDD is a seemingly straightforward multistep process that is 
complicated by common hindrances in the process that require reiterative troubleshooting 
techniques to overcome them.34,36 The first step in this process is always identifying a target 
protein of interest and, either through previous research or experimental methods, obtaining a 
structural model of the protein. If experimental methods are required, the first common 
hindrance is usually the purification of the protein. The procedures used depend on the type of 
protein and its various properties, but most often problems arise as a result of solubility 
issues.36,37 Upon obtaining a purified sample the process of determining the protein structure 
begins; this typically entails using x-ray crystallography, NMR, or cryo-EM.  
 Upon having structural information for a protein of interest the next step is identifying a 
target site for drug development. Most commonly this is an enzymatic active site, but can also be 
protein-protein interfaces, natural ligand binding sites, sites that induce allosteric regulation of 
protein function, or computationally determined hotspots that are favorable for the binding of 
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small molecules.34 Once a target site for drug development has been identified, screening for hit 
compounds can begin. The process of screening is traditionally carried out through either high 
throughput screening (HTS) or virtual screening (VS). When using HTS researchers screen large 
compound libraries (typically >1000 compounds) with an assay that can appropriately measure 
the activity of these compounds against the target of interest in order to establish binding 
affinities for the compounds.38,39 The strength of using HTS is the ability to obtain biochemical 
or biophysical data for the binding of compounds to the target of interest. The drawbacks to this 
method are the costs associated with it and the relatively low success rates of lead hits making it 
through the optimization process due to poor ADME (absorption, distribution, metabolism, 
excretion) and toxicity profiles, especially given the amount of time, effort, and resources needed 
when carrying out such experiments.39 As previously mentioned, the other option is virtual 
screening which employs using the computational model of the target of interest, outlining the 
previously identified binding site, and using computer simulations to screen massive digital 
compound libraries (typically > 4 million compounds) for their ability to bind to that site. These 
simulations are carried out using force field calculations and simplified quantum mechanical 
algorithms to determine the free energy of ligand binding and rank the ligands in order of 
likelihood of being able to bind to the target protein.40 The drawbacks to this method are the lack 
of biochemical and biophysical data and the error rate resulting from the need to ignore certain 
variables in the calculations due to the complexity of calculating protein-ligand interactions and 
the relatively limited computational power of modern day computers.40-42  
 After having identified lead hit compounds, the next goal is to optimize these compounds 
in order to improve their specificity and affinity for the protein of interest at the target binding 
site.34 This is accomplished first by determining the actual structure of the ligand-protein 
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complex in order to analyze all the molecular interactions that are involved in the binding of the 
ligand to the target protein.34,43 Generally these structures are determined using x-ray 
crystallography,36 but with recent increases in the resolution capabilities of cryo-EM, complex 
structures have been determined using this technique as well.44,45 The process of optimization is 
carried out by making additional increases to affinity, along with increases to specificity of the 
ligand for the target binding site by adding functional groups to the ligand that can interact with 
other nearby residues thus increasing the number of favorable interactions with the protein.34,38,43 
Functional groups may also be swapped out from the initial hit in an effort to improve ADME 
profiles, reduce toxicity of the compound, to ensure it is not a PAINS (pan-assay interference 
compound), to reduce potential off target effects, or any other reason that could help improve the 
quality of the hit compound based on the structural and known data about the target protein that 
is relevant.46 Another way chemical space may be explored is simply by searching for analogues 
of the hit compound through various compound libraries and then testing those analogues against 
the target protein either using an assay or through VS. Regardless of how the novel compound 
hits are found, the reiterative process of drug optimization then generally starts all over again and 
this process is repeated until one of the compounds obtained reaches a satisfactory level of 
affinity and specificity for the target of interest. 34,38  
1.3.1 Fragment-Based Drug Design 
 Fragment-based drug design (FBDD) is a form of SBDD but utilizes small fragment 
molecules (compounds with molecular weights generally < 300 Da) as the initial starting point 
for drug discovery.47 The benefits of FBDD are: the reduction in necessary computational power 
when using virtual screening due to significantly reduced conformational sampling required, 
precision in targeting specific subpockets within the desired ligand target site, thus capitalizing 
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on valuable chemical spaces, and providing acutely potent compounds through combining 
multiple fragments into a single high affinity compound.48 FBDD is restricted to NMR, Surface 
Plasmon Resonance (SPR), and x-ray crystallographic techniques for implementation and 
generally cannot be carried in conjunction with HTS. This is due to the high level of sensitivity 
necessary to use fragments (which is possible with NMR and the more advanced SPR systems) 
or the ability to use high concentration of compound (which is possible when developing 
complex structures with protein crystals) to overcome the generally weak affinity of the initials 
hits.47,48  FBDD has often become favored by many researchers over more traditional methods 
such as HTS for development of lead compounds due to the cost effectiveness of virtual 
screening, the increased amount of chemical diversity that can be screened using the FBDD 
approach, and the relatively high hit rate through rational prioritization and early elimination of 
false positives typically found in screening.49,50 
1.4 Molecular Docking 
 Molecular docking is a computational method of predicting the binding pose of 
molecules with various macromolecular structures.33,34,46 It allows for the screening of massive 
compound libraries against targets of interest and has become an invaluable tool for the process 
of SBDD.34,35 Docking programs are able to predict the binding poses of large compound 
libraries by using atomic models of the macromolecule that is being targeted in conjunction with 
simplified molecular mechanics to calculate force fields, which are parameters and functions that 
allow for the calculation of the potential energy of molecular systems.51 The potential energy 
calculations are used to probe which ligand conformations have the highest probability of 
binding to the target molecule and those calculations are used to rank the most likely 
conformations for all the ligands.52,53  
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 The first problem the docking program must confront is the flexibility of the millions of 
ligands in the compound library. In order to tackle the issue of flexibility, the docking program 
must find a way to sample all the possible conformations of ligands and interacting residues.46,52 
All docking programs accomplish this by employing sampling algorithms. There are three main 
types of sampling algorithms that can be employed by docking programs: systematic, stochastic, 
and deterministic searches.54 Systematic searches sample all the degrees of freedom for the 
ligand; however, this methodology by itself can be incredibly computationally taxing so typically 
specific types of systematic searches are employed to improve efficiency, such as hierarchal 
searches.55,56 Hierarchal searches take advantage of the tautology of massive multi-conformation 
compound libraries by organizing ligands into hierarchal groups that allow the docking software 
to quickly eliminate common conformations, which would introduce steric clashes with the 
target and minimize redundant calculations.56 Stochastic search algorithms generate different 
conformations of the ligands by applying randomized alterations to the positioning and torsion 
angles of the compounds and then evaluate these alterations by using energy functions to 
determine if the position and torsion angles of each subsequently generated conformation is 
higher or lower in energy when compared to the previous one.57,58 These types of searches 
include the Monte Carlo algorithm with the Metropolis criterion and the genetic algorithm.59 
Deterministic search algorithms attempt to increase the accuracy of virtual screening by not only 
accounting for ligand flexibility but receptor flexibility as well.54 These types of searches use 
molecular dynamics (MD) simulations and energy minimization, which make them incredibly 
time consuming to carry out. Due to the time consuming nature and computationally intensive 
requirements of MD simulations researchers have proposed using them in conjunction with 
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hierarchical search algorithms by running MD simulations on selected compounds found from an 
initial hierarchical search in order to determine which ligands to investigate further.60,61 
The problem of conformational sampling is not the only issue docking programs must 
overcome, they also face the challenge of estimating the binding affinity for the compounds in all 
of their possible conformations, and this is accomplished through the use of scoring 
functions.40,41,46 Scoring functions allow the docking software to determine the most 
energetically favorable ligand binding pose when interacting with the target site on the 
macromolecule of interest by assessing the estimated binding affinity of each sampled 
conformation.31,52,62 There are several categories of scoring functions, each with its own 
strengths and weaknesses: physics-based, empirical, knowledge-based, and descriptor-based.63 
Physics-based scoring functions rely on molecular mechanics and force field parameters to 
estimate the binding affinity of the compound library.62,64 The force fields used in the potential 
energy calculations include the stretching of bonds, the energy associated with bond angle 
bending, the torsion or the energy associated with the rotation of all the bonds, all the non-
bonded terms, which includes van der Waals and electrostatic interactions, the desolvation 
energy of the target molecule, and potential hydrogen bonds involved in the ligand-receptor 
interaction.51-53 Empirical scoring functions use various molecular mechanical components such 
as hydrophobic interactions, hydrogen bonds, and intramolecular strain but then weight these 
components with coefficients and other additional terms from experimentally determined data in 
order arrive at a final score.31,52,63 Knowledge-based scoring functions employ the use of 
statistics-based force field parameters to calculate the energy potentials of the ligand and the 
target molecule and then use an inverse Boltzmann analysis to determine the effect of the 
interatomic distance on these energy potentials.31,52,63 In descriptor-based scoring functions the 
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docking software utilizes previously determined quantitative structure-activity relationship 
(QSAR) data by giving descriptors to the properties of the individual ligands found in the 
compound library, the target molecule, and the interaction patterns found between these two. 
These descriptors can then be plugged into a machine-learning algorithm that will generate the 
most statistically probable binding scores for these ligand-target complexes.63 
Molecular docking has become a critical part of any SBDD effort through its low cost, 
high rates of success, and ability to overcome complex problems through the use of 
conformational sampling algorithms and scoring functions.31,43,50  Molecular docking is not 
without its drawbacks and weaknesses, despite the rapid advances and surmounted obstacles 
within the field of computational chemistry. Due to the overwhelming complexity of any 
molecular interaction, especially when considering macromolecular interactions with ligands, 
accurate prediction of the behavior of these molecules using computational models remains a 
challenge of the highest order and the results of a molecular docking run still cannot be used as 
definitive evidence for said interactions.31,40,52 However, as molecular docking algorithms 
advance and computers become more powerful in terms of their speed and processing abilities 
this branch of research will flourish. 
1.4.1 ZINC Database 
 The ZINC database is an online database of compounds that are able to be used for the 
purpose of molecular docking and are freely available for purchase. It is an open-access platform 
and used regularly by researchers for ligand discovery. The database is replete with over 500 
million protomers in biologically relevant forms and ready for use in molecular docking 
simulations. ZINC is made up of compounds from 266 different vendors and 122 annotated 
catalogs and is frequently updated to ensure all compounds are still purchasable.65 It is also 
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functionally organized into tranches, which allow all of the compounds to be separated from one 
another based on wait time for delivery and various properties including molecular weight, log P 
values, reactivity, pH representations, and overall charge of the molecule.65 ZINC also offers 
predefined subsets consisting of common value ranges for the molecular weight and log P 
values, which include shards, fragments, lead-like, and drug-like. The most common ranges are 
the fragment (200-300 Da and log P values between -1 and 3.5) and lead-like (300-375 Da and 
log P values also between -1 and 3.5).65 The fragment subset offers lower affinity compounds 
that are ideal starting points for FBDD efforts that implement x-ray crystallography, NMR, and 
SPR due to the ability to use high levels of compound concentration that are normally 
unattainable when using bioactivity assays.35,66 The lead-like subset offers higher affinity 
compounds that are typically suited for use in inhibitor discovery efforts, but can also be used as 
initial points of inquiry for SBDD projects.35,66 In an effort to assist non-experts in 
chemoinformatics and computational biology, ZINC also allows the user to search for 
compounds with known bioactivity at varying stages of research (i.e., in vitro, in vivo, in trials, in 
man, in cells, and FDA approved), compounds with varying degrees of biogenic origins (i.e., 
endogenous, metabolite, or biogenic), and analogs of compounds of interest.65 
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Chapter 2: 
Dual Targeting the Lipid A Biosynthesis Pathway 
2.1 Overview 
The lipid A biosynthesis pathway is essential in Pseudomonas aeruginosa. LpxA and 
LpxD are the first and third enzymes in this pathway respectively, and are regarded as promising 
antibiotic targets. The unique structural similarities between these two enzymes make them 
suitable targets for dual-binding inhibitors, a characteristic that would decrease the likelihood of 
mutational resistance and increase cell-based activity. We report the discovery of multiple small 
molecule ligands that bind to P. aeruginosa LpxA and LpxD, including dual-binding ligands, 
demonstrating the feasibility of developing such small molecules targeting lipid A biosynthesis. 
The binding poses were determined for select compounds by X-ray crystallography. The new 
structures revealed a previously uncharacterized magnesium ion residing at the core of the LpxD 
trimer. In addition, ligand binding in the LpxD active site resulted in conformational changes in 
the distal C-terminal helix-bundle, which forms extensive contacts with acyl carrier protein 
(ACP) during catalysis. These ligand-dependent conformational changes suggest a potential 
allosteric influence of reaction intermediates on ACP binding, and vice versa. Taken together, 
the novel small molecule ligands and their crystal structures provide new chemical scaffolds for 
ligand discovery targeting lipid A biosynthesis, while revealing structural features of interest for 
future investigation of LpxD function. 
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2.2 Introduction 
2.2.1 The Problem of Antibiotic Resistance 
Antibiotic resistance is a worldwide threat that challenges our ability to successfully treat 
bacterial infections, reducing treatment success and exhausting health care resources.1 Infections 
caused by antibiotic-resistant Gram-negative bacteria (GNB) are particularly intractable due to 
the presence of an additional outer membrane that protects the bacterial cell from harsh 
environments and antibiotics.67 The outer leaflet of this membrane primarily consists of 
lipopolysaccharide (LPS).68 Although LPS is nonessential in some organisms (i.e. A. baumannii, 
N. meningitidis), it is essential in many important GNB such as P. aeruginosa, a common and 
potentially life-threatening nosocomial pathogen that is naturally resistant to many 
antibiotics.1,67-71 Compounds targeting LPS synthesis provide an excellent opportunity for the 
development of new antibiotics with a novel mechanism of action.  
2.2.2 LPS Components 
LPS is made of three components: 1) a linear chain of repeating saccharide units known 
as the O-antigen, 2) an oligosaccharide core domain, and 3) lipid A, a core glucosamine 
disaccharide that is connected to multiple fatty acid chains of various length.68,71 Lipid A has 
several interesting properties that underscore its importance to GNB; for one, lipid A is the 
minimal component of LPS required for cellular viability in most Gram-negative bacteria.68,69,72 
Additionally, lipid A is the primary antigenic determinant of LPS and is the offending chemical 
species that precipitates septic shock.68,73,74  
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2.2.3 Lipid A Biosynthesis 
The Lipid A biosynthetic pathway, also known as the Raetz pathway, is highly conserved 
amongst all GNB. LpxA, LpxC and LpxD make up the first three enzymes in the Raetz pathway 
(Figure 2.1).68 In P. aeruginosa, LpxA catalyzes the first reversible first step, transferring a 10C 
hydroxydecanoate fatty acid to the uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) 
substrate through an acyl carrier protein (ACP). In the second step, LpxC catalyzes the zinc-
dependent irreversible deacetylation of the LpxA product, producing UDP-3-O-(3-
hydroxydecanoyl) glucosamine and committing the molecule to this pathway.  LpxD is 
responsible for the reversible third step, in which a β-hydroxydodecanoate is transferred to the 2’ 
amine of UDP-3-O-(3-hydroxydecanoyl) via ACP.75 Six additional enzymatic steps are required 
before the completed lipid A product can be incorporated into the LPS molecule through 
attachment to the core component (Figure 2.1).68,76-78 While LpxC is completely dissimilar to 
LpxA and LpxD, the latter two enzymes share several unique structural features, consistent with 
their functional similarities in catalyzing the transfer of a 10 or 12 carbon chain fatty acid from 
ACP to UDP-GlcNAc through a concerted acid-base mechanism.79,80 Both proteins form 
biological homotrimers that contain a left-handed helix fold comprised of multiple parallel β-
sheets.77,79-86 Although P. aeruginosa LpxA and LpxD only have 27% sequence identity, they 
exhibit highly conserved protein backbone and side chain features, particularly at the junctions of 
adjacent β-helix monomers which form the acyl chain binding pocket (Figure 2.5). 
2.2.4 Targeting Lipid A Biosynthesis 
LpxC has been extensively targeted in novel antibiotic discovery and many potent 
inhibitors with bactericidal properties currently exist.87 Whereas LpxA and LpxD are promising 
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drug targets themselves and are known to be essential in E. coli, inhibitor discovery against these 
enzymes has remained largely unexplored with no known small molecule inhibitors having ever 
been identified.69,76 The unique, shared structural similarities also make LpxA and LpxD 
amenable to dual-targeting inhibitors, which offers the advantages of increased potency and 
reduced likelihood of resistance formation.88 The concept of dual targeting early steps of the 
lipid A biosynthetic pathway has previously been supported with a peptide molecule RJPXD33, 
which was found to inhibit both LpxA and LpxD when expressed in E. coli.89 However, the 
clinical utility of such peptide inhibitors is limited due to their inability to penetrate the cell 
envelope. Herein we report the discovery of several small molecules that bind to both LpxA and 
LpxD with μm affinity, identified using a targeted structure-based methodology that utilizes 
molecular docking, Surface Plasmon Resonance (SPR) bioanalysis, and high-resolution 
crystallography.  The structural analysis has offered valuable insights into not only inhibitor 
binding hot spots of LpxA and LpxD, but also allosteric effects of ligand binding in LpxD active 
site, which may play an important role in the LpxD reaction mechanism.    
2.3 Results 
2.3.1 LpxD Crystallization 
The crystal structures of both Pae LpxA and LpxD have been determined previously.81,90 
However, in the published Pae LpxD structure, the thrombin protease recognition sequence of 
the N-terminal His-tag linker is located in the active site, particularly, the uracil binding pocket. 
This obstructs the diffusion of small molecules into the active site, preventing the use of this 
construct in both functional and structural studies of ligand binding. After failed attempts to 
crystallize untagged LpxD following protease cleage, we tested a few variations of this LpxD 
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construct by changing the thrombin protease cleavage site to TEV protease recognition sequence, 
and by excising the first two residues of the protein, His1 and Met2, which are located 
immediately after the N-terminal 20-AA protease site/hexahistidine tag. The resulting crystal 
structure is similar to the published one, with each asymmetric unit of the H3 space group 
containing one monomer which forms a biologically relevant homotrimer through 3-fold 
crystallographic symmetry operation.81 Importantly, the density of the His-tag linker is no longer 
observed in the active site. In fact, whereas the His-tag and the linker is ordered in the previous 
structure, this entire region is disordered in the current structure. However, our failure to 
crystallize untagged LpxD suggests the His-tag may still contribute to the stability of the crystal 
packing interface, despite the lack of an ordered conformation.    
An interesting observation in our new LpxD structure is a well-defined magnesium ion in 
the core of the trimer (Figure 2.2). This magnesium ion, likely from the crystallization buffer, 
coordinates six water molecules and appears to be critical to the stability of the crystal, as 
removing magnesium from the crystallization buffer or chelating the magnesium with EDTA 
eradicates diffraction. A similar but slightly weaker density corresponding to this magnesium ion 
was observed in the previously published structure crystallized in the absence of magnesium in 
the crystallization buffer (PDB ID: 3PMO).81 Although it was modeled as water, the surrounding 
density peaks suggest that it may be a low-occupancy divalent metal ion coordinating six water 
molecules as observed in our new structure.    
2.3.2 Structure-Based Inhibitor Discovery 
In the absence of a functional high-throughput assay and no previously discovered small 
molecule inhibitors, virtual screening of the ZINC small molecule database was performed using 
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DOCK to identify potential compounds that would bind to the LpxA active site.35,56 Specifically, 
the acyl chain binding pocket was targeted because of key, shared residues between LpxA and 
LpxD.  Multiple iterations of docking simulations were performed targeting LpxA, each with 
minor alterations to sampling space and side chain partial charge to favor conformations that 
would engage the targeted residues.  Top scoring compounds (0.5%) were visually inspected. 25 
of these compounds were selected and experimentally assessed against both LpxA and LpxD 
with SPR bioanalysis, a label-free biophysical technology capable of detecting ligand binding 
affinity and quantifying binding kinetics. The results from this study indicated 6 of the 25 
selected compounds (24%) demonstrated micromolar affinity for LpxA, and 2 of these 25 (8%) 
retained similar affinity against LpxD (Table 2.1). R-3-hydroxydecanoyl and UDP-GlcNAc were 
included in the SPR assay as positive controls. While R-3-hydroxydecanoyl was a potent binder 
of LpxA (7.6 μM) and LpxD (41.1 μM), the affinity of UDP-GlcNAc for these two enzymes 
could not be determined by the SPR assay due to poor data quality.  
2.3.3 Complex Crystal Structures of Novel Inhibitors 
To elucidate the molecular interactions between these novel inhibitors and LpxA/D, 
complex crystal structures were determined for two inhibitors, including one crystallized with 
both proteins. The crystal structures of Pae LpxA in its apo and substrate-bound form have 
previously been solved in our laboratory at 1.8 Å and 2.15/2.3 Å, respectively.90 LpxA belongs 
to the P212121 space group with an asymmetric unit consisting of six monomers that form two 
separate biologically relevant homotrimers through a noncrystallographic 3-fold symmetry 
(Table 2.2). This results in six actives sites per asymmetric unit, along with 6 copies of the 
ligand; one at each of the dimer interfaces present in the homotrimers. Interestingly, both ligands 
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have similar chemical characteristics, with two, bridged six-membered rings substituted with a 4-
6 atom acyl chain and a terminal carboxyl group, a chemical species closely resembling its fatty 
acid substrate (Table 2.1).  
For compound 1, two binding conformations for the ligand can be identified, differing 
from one another mainly in the location of the carboxyl group (Fig. 2.3). In one conformation 
(pose 1), the carboxyl group hydrogen bonds with Gn157 main chain and His156 side chain (Fig. 
2.3A). This appears to be the primary conformation for the ligand since 4 out of the 6 copies 
present in the asymmetric unit assume this pose (Figure 2.3A). In the other conformation (pose 
2), the ligand carboxyl group hydrogen bonds with a new conformation of Gln157 side chain 
(Figure 2.3B). The rest of the ligand, including the carbonyl group and the naphthalene ring, is 
positioned identically between the two conformations. In both conformations, compound 1 forms 
hydrogen bonds with both monomers at the dimer interface, including the aforementioned 
contacts with one monomer and a HB with Gly151 side chain from the other monomer.  The 
naphthalene ring establishes multiple van der Waals interactions with residues Asn133, Tyr152, 
His156, Phe166, and Met169, pi-sigma interactions with Val132 and Ala138, a pi-stacking 
interaction with His118, and a pi-alkyl interaction with Ala136. The second observed binding 
conformation is relatively similar.  Compared with the apo LpxA structure, one minor 
conformational change in the protein active site is also observed. This involves the so called 
“hydrocarbon ruler” Met169, a methionine residue that confers substrate specificity based on 
acyl chain length, which shifts upward in order to accommodate the naphthalene ring. 
The compound 2 complex structure with LpxA was solved at 2.0 Å (Figure 2.3C). 
Corresponding ligand density is seen at all 6 active sites within the asymmetric unit, all adopting 
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the same conformation. Many of the interactions formed by compound 1 with LpxA are also 
seen with compound 2, including two hydrogen bonds with Gln157 and Gly151. The carboxyl 
group of compound 2 interacts with the backbone and side chain of His156, which shifts inwards 
to form a HB with its Nπ atom. The benzoxazine group of compound 2 forms pi-alkyl 
interactions with Ala136, Val132 and Ala138, and a pi-sulfur interaction with the hydrocarbon 
ruler, Met169. Unlike the naphthalene ring of compound 1 which is buried in the acyl chain 
pocket, the benzoxazine ring of compound 2 is partially drawn outwards, likely due to the H-
bonding interactions between the substituted amide group of this ring and the catalytic residues 
His121 and Asp70.  
Our sole LpxD complex structure with compound 1 (2.7 A) showed distinguishable 
electron density corresponding to the ligand at the dimer interface formed via crystallographic 
symmetry (Figure 2.4). The fitted binding pose suggests that there are two critical hydrogen 
bonds for the protein-ligand complex formation, both with the backbone nitrogen of two glycine 
residues Gly272 and Gly278 from the adjacent monomers forming the active site. Additionally, 
compound 1 forms extensive van der Waals interactions with residues Met239, Ser259, Gly257, 
Gly272, Gly275, Val277, and Gly290, which are also critical for the hydrophobic contacts with 
the substrate acyl chain. Indeed, structural alignments reveal the decanoyl acyl chain of the 
substrate superimposes closely with the naphthalene ring of compound 1. Additional pi-alkyl 
interactions are seen with Ala253 and Ala254, amide-pi stacking interactions with Ile258 and 
Leu276, and pi-sulfur interactions with Met291 and Met293.  
Two conformation changes are observed in LpxD upon ligand binding, one being Ser259. 
In its apo form, the Ser259 side chain normally points inwards towards the active site, however, 
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the naphthalene ring of compound 1 forces this residue to rotate inwards to avoid steric clash 
(Figure 2.4B). An additional, unexpected shift is also seen outside of the active site, in the distal 
α-helical ACP recognition domain (ARD) domain (Figure 2.4A), comparable to the changes 
observed between the apo structure of E. coli LpxD (PDB 3EH0)79 and the ACP bound forms 
(PDB 4IHF, 4IHG, and 4IHH).91 Given the functional role of this domain in binding and 
releasing ACP bearing one key substrate, it seems likely that this structural shift may play a role 
in the proper functioning of the enzyme.91 
Given the similarity of the binding pockets in LpxA and LpxD, it is not surprising that 
the binding modes for compound 1 are overall similar between the two proteins. Minor 
differences include the overall positioning of compound 1, which is slightly deeper in the LpxA 
active site with the naphthalene ring oriented horizontally, in contrast to LpxD, where the napthal 
ring faces vertically. Additionally, the acyl chain and terminal carboxyl group of the ligand in 
LpxD protrudes slightly out of the pocket (Figure 2.4), rather than upwards, as seen in LpxA 
(Figure 2.3). Similar intermolecular interactions are seen between structures, with three hydrogen 
bonds and five hydrophobic interactions formed in LpxA and two hydrogen bonds and seven 
hydrophobic interactions formed in LpxD.  
2.4 Discussion 
Despite the importance of LpxA and LpxD in Lipid A biosynthesis and their potential as 
antibiotic targets, small molecule inhibitor discovery has been lacking against these two proteins.  
Many details of their enzymatic reactions also remain unclear.  Our results not only provide the 
first examples of small molecule inhibitors targeting LpxA and LpxD, but also demonstrate the 
possibility of designing dual-binding compounds active against both enzymes. In addition, our 
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new LpxD crystal structures shed new light on previously uncharacterized structural features, 
including an intramolecular network, that will deepen our understanding of LpxD catalysis. 
2.4.1 Dual-Targeting Inhibitor Development 
Both LpxA and LpxD catalyze the transfer of a 10- or 12-carbon acyl-chain from ACP to 
GlcNAc.  Despite their low sequence identity, the two proteins share high structural similarity in 
the overall architecture of a homotrimer and in the active site residues, especially in the acyl-
chain binding pockets that reside in the dimer interface of the β-helix trimer core.  The 
similarities between the acyl-chain binding pockets of LpxA/D are highlighted by the discovery 
of a dual-inhibitor peptide for E. coli LpxA and LpxD (with Kd of 20 μM and 6 μM 
respectively),89 whose complex crystal structure with LpxA reveals potential hydrogen bond 
(HB) interactions with the protein backbone amide groups on the β strands as well as non-polar 
interactions with protein backbone and side chains (Fig. 2.3).92 The same backbone functional 
groups, as well as similar side chain moieties, can be found in the acyl-chain binding pocket of 
LpxD. Our recent determination of the P. aeruginosa. LpxA and LpxD crystal structures further 
demonstrates the conservation of binding hot spots between the two enzymes at the atomic level 
(Figure 2.5B). Similar to E. coli proteins, the acyl-chain binding pockets present the same 
backbone functional groups in both enzymes from P. aeruginosa. Many side chains are also 
conserved between the proteins (e.g., Gly151/Gly272 (from LpxA and LpxD respectively, same 
order below), Phe166/Phe287, His121/His242 (the catalytic histidine), or present the same 
functional groups (e.g., Cβ atom of Ser150/Ala271, non-polar hydrocarbons of Val132/Ala253 
and Ile148/Met269). 
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The dual-binding activity of several of our novel inhibitors has demonstrated the 
feasibility of inhibitor discovery targeting LpxA and LpxD simultaneously.  As shown by the 
complex structures of compound 1 bound to LpxA and LpxD, the inhibitor exhibited overall 
similar binding poses in the two acyl-chain binding pockets, revealing both structural similarities 
and differences that can guide future dual inhibitor development.  The charged and polar 
functional groups of compound 1 interact with backbone amide groups shared by both LpxA and 
LpxD.  The naphthalene ring is nestled in the hydrophobic pocket that recognizes the acyl-chain.  
Compared with the LpxA structure, the ligand aromatic ring goes deeper in the LpxD structure, 
consistent with a slightly larger acyl-chain binding pocket in LpxD.  The two complex structures 
also shed light on additional shared binding hot spots that can be exploited for future lead 
optimization.  Particularly, Phe166/Phe287, Val132/Ala253 and Ile148/Met269 provide large 
hydrophobic binding surfaces that can be very valuable for enhancing ligand binding affinity for 
both proteins.   
2.4.2 Allosteric Regulation in LpxD Reaction 
The reaction catalyzed by LpxD follows a sequential ordered mechanism where acyl-
ACP binds first, and holo-ACP dissociates last after the acyl chain is transferred to UDP-
GlcNAc.  The recent determination of a series of E. coli ACP crystal structures in various 
complexes with LpxD provided important insights into the complex interactions between ACP 
and LpxD, and ligand conformations in the acyl-chain binding pocket crucial to ACP release.  
Aside from a β-coil motif, the ARD domain consists mostly of the C-terminal α-helix.  One of 
the most significant observations in the LpxD inhibitor complex is how ligand binding in the 
acyl-chain binding pocket triggers conformational change in the distal C-terminal helix, 
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suggesting crosstalk between the catalytic center and ACP binding site.  This suggests potential 
allosteric regulation of substrate binding in the active site by protein-protein contacts between 
ACP and LpxD, and vice versa, which can possibly play a role in dictating the order of the 
catalytic events in LpxD reaction.  
Our new LpxD crystal structures also shed light on a previously uncharacterized 
magnesium ion at the center of the trimer core.  Although the presence of magnesium in the 
crystallization buffer undoubtedly facilitate its presence in our crystal structure, electron 
densities corresponding to this magnesium and surrounding water molecules was observed in the 
previously determined LpxD structure as well. We hypothesize that magnesium ion can 
potentially stabilize the trimer. Interestingly, research has shown that low magnesium conditions 
in P. aeruginosa leads to alternative lipid A species with unique patterns of acylation through the 
removal of the R-3-hydroxydecanoic acyl chain. These alternate lipid A species are found 
present in isolates of patients with cystic fibrosis and seem to be an adaptation to infecting the 
airways of these hosts.93,94 Similar undiscovered lipidation patterns could occur in response to 
low magnesium conditions in different environments through the mechanism of destabilizing the 
LpxD trimer. However, further investigation is needed to probe the exact role of magnesium in 
LpxD structure and function. 
2.4.3 Issues of Drug Permeability in Targeting Lipid A Biosynthesis 
 Both LpxA and LpxD are located on the cytoplasmic side of the inner membrane of the 
gram negative bacterial cell, despite the final destination of lipid A being the outer membrane.95 
Bacteria overcome the membrane barriers between the location of LPS synthesis and final 
cellular localization by having LPS export proteins that transport the intermediates and final 
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product across the inner and outer membranes.75 These export proteins include MsbA, the lipid A 
core flippase. They also include the Lpt proteins, which are a group of proteins that form 
multiple protein complexes in order to act as a multifaceted transenvelope protein complex 
capable of transporting LPS across both membranes.75 Due to subcellular localization of LpxA 
and LpxD, and the resultant protection from the multiple cell layers separating the cytosol from 
the extracellular space, utilizing these proteins as drug targets poses a unique challenge. 
Research has shown that even when compared to other Gram negative bacteria, P. aeruginosa 
has particularly low drug permeability due to the outer membrane of the bacteria.96  
The challenge of permeating the gram-negative bacterial cell can be overcome though 
through various techniques that improve the uptake, or decrease the efflux, of bactericidal 
compounds. One method is utilizing rational drug design, such as in the recent study that 
analyzed the penetration of carbapenem in P. aeruginosa using molecular dynamics simulations 
to determine the lowest energy path of uptake for the compound and other natural ligands.97 
Using this information, researchers were able to create a series of analogues for carbapenem that 
allowed for the probing of new structural features to add to the molecule that would allow for it 
to maintain inhibitory activity while reducing dependence on OccD1 proteins for translocation, 
and thus increase permeability towards P. aeruginosa.97 Another method for increasing drug 
permeability in bacterial cells is through the use of Siderophore-conjugated antibiotic 
systems.98,99 Siderophore is a small, high affinity, iron chelator which serves to transport iron 
across cell membranes. By attaching antibiotics to Siderophore, the bacterial transport systems 
used for iron-uptake can be taken advantage of in order to transport the conjugated antibiotic into 
the periplasmic or cytoplasmic spaces of the cell.98,99 One other method for tackling the issue of 
drug permeability is through the use of efflux pump inhibitors (EPIs) given in conjunction with 
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antibiotic medications, such as PAβN and other similar arylamines, which act as broad-spectrum 
EPIs, or the P. aeruginosa MexB specific pyridopyrimidines.100-102 By using EPIs the need for 
high concentrations of compound to reach the intended target is reduced, rather than increasing 
the ability of the drug to enter the system of the bacterial cell more effectively. 
While utilization of the methods for bypassing low permeability in bacterial cells are 
beyond the scope of this project, their application in future research may be worth considering 
should drug permeability become an issue with the newly discovered compounds targeting LpxA 
and LpxD. This would first require cell-based assay testing of the inhibitors and determining if 
the negative results are from a lack of inhibitory properties or from a lack of compound uptake 
into the bacterial cells. Upon establishing the reason for such results, steps can be taken to 
improve the current compounds and make them more effective in the treatment of P. aeruginosa. 
2.5 Conclusions 
LpxA and LpxD are both promising targets for new antibiotic agents against GNB 
bacteria such as P. aeruginosa. Our studies have identified novel scaffolds that can serve as 
starting scaffolds for future inhibitor discovery including dual-binding compounds that 
underscore the structural and functional similarities shared by these two proteins. Furthermore, 
the reported X-ray structures for LpxA and LpxD represent the first published structures of these 
enzymes complexed with non-substrate/product small molecule ligands. Though it was not the 
primary goal of this project, these complex structures reveal unique conformational changes that 
occur in these enzymes. Most notably is the α-helical shift in the ARD of LpxD following ligand 
binding; it is possible that the perturbation of intermolecular interactions between monomers at 
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the interface of the acyl-chain binding pocket induces this conformational shift, an event that 
would elucidate the mechanism of substrate binding and release.  
2.6 Experimental Procedures 
2.6.1 Purification of Recombinant LpxA 
The plasmid pET28b (Achaogen) containing the N-terminal His-tagged P. 
aeruginosa LpxA sequence was transformed into Rosetta (DE3) pLysS cells (Novagen). The 
cells were incubated in 50 ml of LB media supplemented with 35 μg/mL chloramphenicol and 50 
μg/mL kanamycin at 20°C overnight. Then 10 ml of overnight culture was added to 1 L of LB 
media containing 35 μg/mL chloramphenicol and 50 μg/mL kanamycin and incubated at 37 °C 
until the OD600 reached 0.6–0.8. The protein expression was induced with 0.5 mM IPTG, and 
incubation continued at 20 °C overnight. The culture is then centrifuged at 5,000 g for 10 
minutes and the pellet is resuspended in 10 ml the lysis buffer (20 mM Tris-HCl, pH 8.4, 250 
mM NaCl, 20 mM imidazole, and 10% glycerol). The resuspended pellet was then sonicated on a 
10 second sonication/15 second rest cycle for a total of 15 minutes at an amplitude of 6. This is 
followed by centrifugation at 40,000g for 40 minutes at 4ºC. The supernatant was then loaded to 
a HisTrap affinity column and eluted with a linear concentration gradient spanning 10-500 mM 
imidazole. The fractions containing LpxA were pooled and concentrated. The sample was loaded 
to a HiLoad 16/60 Superdex 75 column for further purification in thrombin cleavage buffer (20 
mM Tris, pH 8.4, 150 mM NaCl, and 10% glycerol). The peak fractions containing the His-
tagged LpxA were pooled, and the concentration of the protein was determined by OD280. The 
protease thrombin (Roche) was added at a ratio of one unit per milligram of the protein. 
Thrombin was selected as the protease due to it having high specificity and fidelity for the given 
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cleavage sites. After overnight incubation at room temperature, the samples were then loaded 
onto a HisTrap column to remove any uncleaved protein. The flow-through was collected and 
concentrated, followed by gel filtration with the HiLoad 16/60 Superdex 75 column. The protein 
eluted at a peak consistent with the size of the trimeric form. The untagged LpxA was stored at 
−80 °C at 20.0 mg/mL concentration in a buffer containing 20 mM potassium phosphate pH 8.6 
and 250 mM NaCl. The purity of the protein was determined by SDS-PAGE to be >95%. 
2.6.2 Purification of Recombinant LpxD 
The pETMHL plasmid (Addgene) containing the N-terminal His-tagged P. aeruginosa 
LpxD with the 2 amino acid deletion sequence was transformed into cells, which were then 
grown in a 50 ml overnight culture of LB media with 35 µg/ml of chloramphenicol and 50 µg/ml 
of kanamycin at 20ºC. Then 10 ml of the overnight culture was added to 1 L of LB media 
containing 1 ml of 35 µg/ml of chloramphenicol and 50 µg/ml of kanamycin each. These cells 
were incubated at 37ºC for 4 hours until they reached an OD600 of 0.6 to 0.8. Then induction was 
carried out by adding 1 ml of 0.5 M IPTG and further incubating at 20ºC again overnight. The 
culture is then centrifuged at 5,000 g for 10 minutes and the pellet is resuspended in 10 ml of the 
lysis buffer (20 mM Tris-HCl pH 8.4, 300 mM NaCl, 10% glycerol v/v, and 20 mM imidazole). 
The cells are thawed on ice and transferred to a 40 ml beaker. The cells are then sonicated on a 
10 second sonication/15 second rest cycle for a total of 15 minutes at an amplitude of 6. The 
lysate is then centrifuged at 40,000 rpm for 40 minutes at 4ºC. The supernatant is then filtered 
and loaded onto a HisTrap affinity column and eluted with a linear concentration gradient 
spanning 10-500 mM imidazole. The fractions containing LpxD were then collected, pooled, and 
concentrated down using an Amicon filter. The concentration of the protein was checked using 
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OD280. The protein was the loaded to a HiLoad 16/60 Superdex 75 column for additional 
purification along with the storage buffer (20 mM Tris-HCl pH 8.6 and 250 mM NaCl). The 
protein eluted at a peak consistent with the size of the trimeric form. The LpxD was stored at -
80ºC at 35.8 mg/ml. The purity of the protein was determined by SDS-PAGE to be >95%. 
2.6.3 Purification of Biotinylated Avidity-Avi Tagged LpxA and LpxD 
The LpxA and LpxD genes were inserted into BamHI and HindIII site of pAvibir plasmid 
(Achaogen). The The plasmids were transformed into Rosetta DE3 pLysS cells, which were then 
grown in an overnight culture of 50 ml LB media with 100 µg/ml ampicillin and 35 µg/ml 
chloramphenicol at 20ºC. Then 10 ml of the overnight culture was added to 1 L of LB media 
again with 100 µg/ml ampicillin and 35 µg/ml chloramphenicol and incubated at 37ºC until 
OD600 was at least 0.6 but less than 0.8. Protein expression was induced by adding 1 ml of 0.5 M 
IPTG, along with 10 ml of fresh biotin solution at a concentration of 5 mM. The culture was then 
incubated at 20ºC with vigorous shaking overnight. Cells were harvested by centrifuging the 
solution for 10 minutes at 4000 g at 4ºC. The supernatant was discarded and the cell pellet was 
then resuspended in 10 ml of the lysis buffer (10 mM Tris pH 8.4, 300 mM NaCl, 20 mM 
Imidazole, and 10% glycerol v/v) and a single dissolved protease inhibitor tablet. The 
resuspended cell pellet was then transferred to a 50 ml beaker for sonication. The cells were then 
sonicated on a 10 second sonication/15 second rest cycle for a total of 15 minutes at an 
amplitude of 6. The lysate was then transferred to a centrifuge tube and centrifuged at 35,000 
rpm for 35 minutes at 4ºC. The supernatant was then filtered and loaded onto a HisTrap affinity 
column and eluted with a linear concentration gradient spanning 10-500 mM imidazole. The 
fractions containing protein were then collected, pooled, and concentrated down using an 
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Amicon filter. The concentration of the protein was checked using OD280. The protein was the 
loaded to a HiLoad 16/60 Superdex 75 column for additional purification along with the storage 
buffer (20 mM Tris pH 8.6, 250 mM NaCl, and 1 mM EDTA). The protein eluted at a peak 
consistent again with the trimeric form of the protein. The protein was stored at -80ºC at 7.9 
mg/ml for LpxA and 16.1 mg/ml for LpxD. The purity of the protein was determined by SDS-
PAGE to be >95%. 
2.6.4 LpxA Crystallization 
Qiagen crystallization screens JCSG suites I–IV, AmSO4, MPD, and Core I-II, were 
screened using a Phoenix nanodispenser, and 0.2 and 0.4 μl aliquots of protein solution (14.3 
mg/ml), each with 0.2 μl of well solution, were used to search for crystallization conditions. P. 
aeruginosa LpxA readily crystallized under many conditions, producing cuboidal crystals of 
poor X-ray diffraction quality. Crystals with an almond-like morphology emerged in 20% (w/v) 
PEG 1000, 0.2 M calcium acetate, and 0.1 M imidazole, pH 8.0, which diffracted to high 
resolution but inconsistently. The crystallization condition was optimized to 12% (w/v) PEG 
1000, 0.2 M calcium acetate, and 0.1 M imidazole, pH 7.0 with a drop ratio of 1 μl of protein to 
2 μl of well solution and 0.5 μl of seed stock. The crystals appeared within 2–4 days and 
measured up to 0.1 mm in length. An additional 750 nl of protein is added to the drop after the 
crystals have formed to increase the size of the crystal, which requires an addition 2-4 days of 
growth. 
Compound 1 and 2 complex structures with LpxA were obtained by transferring apo 
crystals into crystallization solution containing 20 mM of each respective compound and 10% 
DMSO and then they were soaked for 24 hours. After the 24 hour soak the crystals were 
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transferred to another crystallization buffer containing 25% glycerol and immediately flash 
frozen in liquid nitrogen.  
2.6.5 LpxD Crystallization 
Qiagen crystallization screens Core I-IV, JCSG suites I–IV, and AmSO4 were screened 
using a Phoenix nanodispenser, and 0.2 and 0.4 μl aliquots of protein solution (29 mg/ml), each 
with 0.2 μl of well solution, were used to search for crystallization conditions. P. aeruginosa 
LpxD readily crystallized under many conditions, producing crystals of poor X-ray diffraction 
quality or of poor stability making them unable to be mounted into loops for diffraction analysis. 
Crystals with a cuboidal-like morphology emerged in 20% (w/v) PEG 3350 and 0.2 M 
magnesium acetate which diffracted to high resolution consistently. The crystallization condition 
was optimized to 12% (w/v) PEG 3350 and 0.2 M magnesium acetate with a drop ratio of 2 μl of 
protein to 3 μl of well solution and 0.5 μl of seed stock. The crystals appeared within 21-28 days 
and measured up to 0.1 mm in length. 
The apo crystals were transferred to another crystallization buffer containing 25% 
glycerol and immediately flash frozen in liquid nitrogen. Compound 1 complex structure with 
LpxD was obtained by transferring apo crystals into crystallization solution containing 20 mM 
compound 1 and 10% DMSO and then they were soaked for 51 hours. After the 51 hour soak the 
crystals were transferred to another crystallization buffer containing 25% glycerol and 
immediately flash frozen in liquid nitrogen. The compound 2 complex structure with LpxD was 
obtained by transferring apo crystals into crystallization solution containing 20 mM compound 2 
and 4% DMSO and then they were soaked for 24 hours. After the 24 hour soak the crystals were 
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transferred to another crystallization buffer containing 25% glycerol and immediately flash 
frozen in liquid nitrogen. 
2.6.6 Data Collection and Processing 
X-ray diffraction data for the LpxA complex structures with both compounds 1 & 2 were 
collected at the SER-CAT BM beamline at the Advanced Photon Source (APS) within Argonne 
National Laboratory (ANL). X-ray diffraction data for the apo crystal and compound 2 complex 
structure with LpxD were collected at the SER-CAT ID beamline at the same synchrotron. X-ray 
diffraction data for the compound 1 complex structure with LpxD was collected at the SBC BM 
beamline which is also at APS within ANL. All data sets were indexed and integrated using 
iMOSFLM103, scaled with Scala, and structures solved using Molrep104; all of these programs 
can be found in the CCP4 suite.105 Molrep uses the method of molecular replacement to solve 
structures so for the LpxD crystals the structures were solved using the previously solved P. 
aeruginosa LpxD structure (PDB ID: 3PMO) as the model. All LpxA crystals structures were 
solved using the previously solved P. aeruginosa LpxA structure (PDB ID: 5DEM) as the model. 
All model rebuilding of the solved structures was done using Coot106, while all the refinements 
were carried out in the program Refmac5107 also found in the CCP4 suite. 
2.6.7 Surface Plasmon Resonance 
All experiments were conducted using a Biacore 4000 instrument with a CM5 chip at 
25ºC. Avi-LpxA (31.6 kDa, 7.9 mg/ml stock concentration) and Avi-LpxD (39.8 kDa, 16.1 
mg/ml stock concentration) were used as ligands to capture onto the Neutravidin immobilized 
CM5 chip surface. Eighty-two different compounds were used as analytes. Neutravidin (60 kDa, 
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10 mg/ml) was diluted in 10 mM sodium acetate buffer at pH 4.5 (1:50 dilution, 200 µg/ml 
diluted concentration) and immobilized to a level of ~18000 RU, using standard amine coupling 
chemistry. This Neutravidin was immobilized onto all spots (Ss) of all flow cells (FCs). PBS-P 
(20 mM Phosphate buffer, pH 7.4, 2.7 mM KCl, 137 mM NaCl, 0.05% v/v surfactant P20) was 
used as the immobilization running buffer. S3 off all FCs were used as the reference spot. Avi-
LpxA was diluted (1:75 dilution, 105.3 µg/ml diluted concentration) in PBS-P and injected onto 
S1 of all FCs (FCs 1-4). Avi-LpxD was diluted (1:75 dilution, 214.7 µg/ml diluted 
concentration) in PBS-P and injected onto S5 of all FCs. The ligands were captured in the 
presence of PBS-P. Based on the captured response values, theoretical Rmax values were 
calculated for the lowest and highest MW analytes. The Rmax values assum 1:1 interaction 
mechanism. Overnight kinetics were performed for all compounds in the presence of PBS-P+1% 
DMSO buffer. Contact time and dissociation time used in screening experiments were 60 
seconds and 300 seconds respectively. Injected analyte concentrations were 0 µM, 2.5 µM, 5 
µM, 10 µM, 20 µM, and 40 µM. The compounds were injected in triplicate for each 
concentration. Data from overnight kinetics were evaluated by steady state affinity or 1:1 
kinetics models fitting. 
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Compound Structure LpxA (µM) Χ2 (LpxA) LpxD (µM) Χ2 (LpxD) 
1 
 
NA NA NA NA 
2 
 
19.5 0.2196 36.7 0.2282 
3 
 
16.7 4.124 NB NB 
4 
 
13.6 0.3219 NB NB 
5 
 
2.1 0.4179 NB NB 
6 
 
64.6 0.2646 21.6 0.1569 
7 
 
7.6 0.3253 41.1 0.1254 
  
Table 2.1. Surface Plasmon Resonance Assay Hits. The eight compounds we were able to 
confirm bound to LpxD through using an SPR assay. 
 
A NB = No Binding; NA = Kd could not be determined via fitting due to poor data quality 
B Χ2: The average deviation of the experimental data from the fitted curve, where lower 
numbers indicate a better fit. Each compound concentration was tested in triplicates and all 
data were fitted onto one dose-response curve.   
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Data Collection 
     
      
Structure (PDB ID)  LpxD Apo LpxD +236 LpxA+236 LpxA+251 
Space Group  H3 H3 P212121 P212121 
Cell Dimensions      
a, b, c (Å)  104.78 105.07 80.28 80.16 
  104.78 105.07 82.5 82.52 
  94.12 96.54 221.9 223.45 
a, b, g (°)  90 90 90 90 
  90 90 90 90 
  120 120 90 90 
Resolution (Å)  52.39-1.52 52.51-2.72 77.33-2.00 57.50-2.00 
No. Reflections  59298 10690 96184 85168 
Rmerge (%)  9.8 20 12.5 11.8 
I / óI   13.6 (2.0)* 5.1 (2.1)* 8.0 (2.0)* 10.9 (2.3)* 
Completeness (%)  100.0 100.0 96.2 84.6 
Redundancy  11.4 (11.0) 5.5 (5.6) 4.4 (4.4) 5.2 (5.5) 
      
      
      
      
Refinement      
      
Resolution (Å)  52.39-1.52 52.51-2.72 77.33-2.0 57.50-2.0 
Rwork/Rfree (%)  17.86/19.3
9 
20.79/29.36 20.43/24.49 19.63/24.54 
No. Heavy Atoms      
Protein  2606 2458 11942 11886 
Ligand/Ion  1 18 108 137 
Water    162 22 159 116 
B-Factors (Å2)      
Protein  19.99 49.53 28.97 25.58 
Ligand/Ion  26.6 45.5 29.31 21.55 
 Water  29.45 24.34 25 16.66 
Ramanchandran Plot       
Most Favored Region(%)  98.8 90.5 95.3 94.8 
Additionally Allowed (%)  1.2 7.1 4.6 4.8 
Generously Allowed (%)  0.0 2.4 0.1 0.3 
      
   *Values in parentheses represent highest resolution 
Table 2.2. X-Ray Data Collection and Refinement Statistic 
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Figure 2.1. Lipid A Biosynthesis Pathway. In Pseudomonas aeruginosa LpxA 
catalyzes the first step in the lipid A biosynthetic pathway (Raetz pathway) by mediating 
the reversible transfer of β-hydroxydecanoate from the Acyl Carrier Protein (ACP) onto 
the 3-OH position of UDP-GlcNAc and forming an ester bond. LpxD catalyzes the third 
step in the Raetz pathway, the reversible transfer of a β-hydroxydodecanoate from ACP 
onto the 2-NH2 of the UDP-3-O-(3-hydroxydecanoyl) glucosamine through the 
formation of an amide bond.  
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A 
B 
Figure 2.2. Magnesium Ion and Coordinated Waters at the Core of LpxD Trimer. The 
2Fo-Fc electron density map is shown at 2.0 σ. (A) Overhead view of the LpxD trimer (green) 
with well defined electron densities of a magnesium ion (green sphere) coordinating with six 
water molecules (red spheres) at the core of the trimer. (B) Side view of LpxD with the C-
terminal helix bundle shown at the top.  
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Figure 2.2. Magnesium Ion and Coordinated Waters at the Core of LpxD Trimer. 
(Continued) The 2Fo-Fc electron density map is shown at 2.0 σ. (C) Zoomed in side view of 
LpxD and the magnesium ion. Hydrogen bonds are indicated by black dashed lines.  
  
C 
Cys255 
Cys255 
Cys255 
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Figure 2.3. LpxA Complex Structures with Novel Inhibitors. Compounds 1 (orange) and 2 
(purple) both bind to LpxA (green). Hydrogen-bonds are shown as dashed lines. The 
unbiased Fo – Fc map (contoured at 2.0 σ) allows for the identification of the binding poses of 
compound 1 in the active site. Two unique binding poses are observed for compound 1 in 
different LpxA active sites of the same trimer. (A) Pose 1 of compound 1 has the carboxyl tail 
forms two hydrogen bonds with Gn157 main chain and His156 side chain. (B) Pose 2 of 
compound 1 hydrogen bonds with a new conformation of Gln157 side chain. (C) The binding 
pose of compound 2. 
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Figure 2.4. LpxD Complex Structure with Compound 1. The compound is colored in orange. 
HBs are shown as dashed lines. (A) Superimposition of the apo (purple) and complex (green) 
protein structures shows a shift of the C-terminal alpha helix region of the protein in response to 
ligand binding. (B) The unbiased Fo – Fc map (contoured at 2.0 σ) identifies the binding pose of 
the compound 1 in the active site.  
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Figure 2.5. Structural Alignments of P. aeruginosa LpxA & LpxD. (A) Superimposition of 
the overall LpxA (green) and LpxD (magenta) trimers shows high levels of conservation for the 
backbone structure. (B) Similarities in the binding hot spots of LpxA (green) and LpxD 
(magenta). The acyl-chain of the LpxA-product complex (yellow) is shown to show the active 
site. His121 and His242 are the catalytic histidine in LpxA and LpxD respectively. (C) 
Compound 1 exhibits a comparable binding pose in LpxA (green) and LpxD (magenta). 
 C B 
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Chapter 3: 
Analyzing Mechanisms of Action for β-Lacatamase Resistant Antibiotics 
3.1 Overview 
  There is a lack of understanding in the literature about the countering effects towards 
antibiotic resistance displayed by temocillin, why despite temocillin’s broad spectrum activity 
against other resistant strains it appears to be ineffective in the treatment of Pseudomonas 
aeruginosa, and the role it’s 6-α-methoxy group plays in binding to Penicillin Binding Proteins 
(PBPs). In order to solve these problems, structural analyses were carried out comparing 
complex structures between PBPs with temocillin and ticarcillin (the parent compound of 
temocillin), which only varies from temocillin in its lack of a 6-α-methoxy group. Such studies 
will allow for improved broad spectrum β-lactamase inhibitors and ideally lead to new antibiotic 
treatments for resistant strains of P. aeruginosa seen in the clinic. 
3.2 Introduction 
3.2.1 Penicillin Binding Proteins and Traditional β-Lactam Antibiotics 
 PBPs are bacterial membrane-bound enzymes located in the periplasm of the cell that are 
responsible for the formation of the peptidoglycan cell wall.108,109 Bacteria synthesize their cell 
walls through the formation of N-acetylglucosamine-N-acetyl muramic polymers.108,109 After 
being synthesized, these polymers get polymerized through the linking of the disaccharide 
peptides (glycosyltransferase activity) and through covalent bond formation at the D-alanine 
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residues of the muramyl pentapeptides (transpeptidase activity) (Figure 1).108,109 This enzymatic 
activity is carried out by the PBPs in order to form the highly-ordered peptidoglycan cell 
wall.108,109 Every species of bacteria expresses multiple types of PBPs and these enzymes can be 
classified into two subgroups: high-molecular mass (HMM) PBPs and low-molecular mass 
(LMM) PBPs.110 The HMM PBPs can be further divided into two subclasses: class A enzymes 
which catalyze both the glycosyltransferase activity and the transpeptidase activity and class B 
enzymes, which are capable of only transpeptidase catalysis.110 The necessity, for cell survival, 
of having functional copies of these different types of PBPs varies from species to species.110 β-
lactams are compounds that irreversibly inhibit the catalytic function of these enzymes by 
mimicking the D-alanine-D-alanine substrate and then forming of a covalent bond between their 
β-lacatam ring and the active site serine of the PBPs.108,109 By preventing the PBPs from cross-
linking the polymers, they induce disruptions in the cell wall integrity which causes the bacterial 
cell to lyse and results in cell death.108,109 
3.2.2 The Rise of β-Lacatamases and Antibiotic Resistance  
 Since the introduction of antibiotics, bacteria have evolved various mechanisms of 
resistance to combat these drugs and their ability to kill the cells.4 The most common mechanism 
seen in bacteria is the encoding and expression of β-lactamase proteins.111 These enzymes 
degrade the activity of β-lactam antibiotics by forming an acyl-enzyme complex with the β-
lactam ring. The enzymes then release a hydrolyzed compound, which can no longer interact 
with the PBPs (Figure 2).111 Such enzymatic activity has rendered many known antibiotics 
clinically useless, due to their high susceptibility to degradation by these enzymes.111 There are 
four classes of β-lactamase enzymes, separated into classes A, B, C, and D.112 Classes A, C, and 
D share a conserved catalytic serine within their active site that is responsible for the hydrolysis 
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of the β-lactam compounds, whereas class B is made up of the metallo-enzymes. Class B 
enzymes rely on the presence of a catalytic metal ions to properly function and do not form an 
acyl-enzyme complex during their mechanism of action.112 Additionally, there are some β-
lactamase proteins encoded by different strains of bacteria that have the ability to hydrolyze a 
wide range of different β-lactam compounds called extended-spectrum β-lactamases (ESBLs).113 
β-lactamases and the many other mechanisms of antibiotic resistance pose great challenges for 
researchers and clinicians to overcome in order to prevent this epidemic from becoming a 
prevalent crisis.    
3.2.3 Renewed Clinical Relevancy of Temocillin 
Due to the rise in antibiotic resistance in the clinical setting many healthcare providers 
have turned to older antibiotics, which saw a decline in clinical use prior to the evolution of 
newer antibiotic resistant strains, in an effort to find treatments that will work against these novel 
forms of resistance; one of these clinically forgotten antibiotics with new relevancy is 
temocillin.114,115 Temocillin is a broad spectrum carboxypenicillin used in the treatment of gram-
negative bacteria that display multidrug resistance in the clinical setting due to 
carboxypenicillin’s ability to resist hydrolyzation by β-lacatamase proteins (Figure 3).116 
Temocillin’s mechanism of action, like other β-lactam antibiotics, is carried out by covalently 
binding to the active site of PBPs.117 Temocillin does not, however, show clinically significant 
activity against P. aeruginosa.118 The only PBP that has shown to be essential for cell growth 
and viability of P. aeruginosa is PBP3, which has made it an important drug target for treating 
these infections.119  
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3.2.4 Comparative Analysis of Temocillin and Ticarcillin 
One of the currently known inhibitors of PBP3 is ticarcillin, considered a parent 
compound of temocillin, because they share the exact same structure with the only difference 
being ticarcillin lacking a 6-α-methoxy group (Figure 3).120 Ticarcillin is clinically approved for 
treating P. aeruginosa when in conjunction with clavulanic acid, a known β-lacatamase 
inhibitor.121,122 The two compounds are administered in combination with one another because 
ticarcillin is able to be degraded by β-lactamase activity.123 Temocillin though is not hydrolyzed 
by many β-lactamase enzymes commonly seen in the clinic, including AmpC 
cephalosporinases.124,125 This has particular clinical relevancy due to the fact that P. aeruginosa 
encodes the gene for AmpC and can be induced to express this β-lactamase protein.125 Due to the 
difference between temocillin and ticarcillin, in terms of ability to be hydrolyzed by β-
lactamases, it can be inferred that this difference must be the result of the presence of the 6-α-
methoxy group. This group can be observed, on the β-lactam ring of temocillin, to be interfering 
with the ability of these enzymes to carry out their catalytic activity (Figure 3). 
Interestingly, temocillin has shown to be a weak inhibitor of P. aeruginosa growth (MIC 
= 128-256 mg/L), even though it is resistant to β-lactamase activity and has high structural 
similarity to ticarcillin, which displays strong activity against this particular species (MIC = 16-
32 mg/L).118,126 It is not currently understood why temocillin displays weak inhibition of P. 
aeruginosa growth or how temocillin’s molecular mechanism to resist β-lactamase activity 
works. Research has suggested that MexAB-OPrM efflux pump encoded by P. aeruginosa is 
what allows the bacteria to remain resistant to the bactericidal effects of the compound.118 The 
efficacy of temocillin is also thought to be affected by a weak binding affinity for PBPs when 
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compared to other β-lactam compounds.127 In either case, the difference in MIC values between 
temocillin and ticarcillin must be related to the presence of the 6-α-methoxy group seen on the β-
lactam ring of temocillin.  
In order to determine the exact role that the 6-α-methoxy group plays in the binding of 
temocillin to PBPs, comparative analysis with ticarcillin was carried out through the 
development of complex structures, SPR analysis, and fluorescence polarization assays for P. 
aeruginosa PBP3. Further structural information was determined by solving a complex structure 
of CTX-M-14 β-lactamase with temocillin in order to compare modes of binding and studying 
the mechanism by which temocillin prevents serine β-lactamase activity. The combination of the 
experiments carried out in this research were done in an effort to further the goal of designing 
better drugs that counteract the mechanisms of antibiotic resistance employed by P. aeruginosa 
seen in the clinic. 
3.3 Results 
3.3.1 Fluorescence Polarization Assays 
 Due to the essential role of PBP3 in the growth of P. aeruginosa, it is essential to look at 
and compare the binding kinetics of ticarcillin versus temocillin in order to determine why these 
compounds have such different efficacies in this particular species. In order to resolve the 
various binding constants, fluorescence polarization assays were carried out using the 
commercially available fluorescence labelled penicillin called bocillin.128 This compound binds 
to PBP3 with strong affinity but also has an attached fluorophore that absorbs light at a 
wavelength of 490 nm and emits at 520 nm. When bound to PBP, the fluorescence anisotropy of 
bocillin increases and can be calculated by measuring the polarization properties observed when 
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exciting the fluorophore on the molecule with plane-polarized light. The binding constants can 
be determined from the fluorescence anisotropy of the molecule due to the fact that when 
bocillin is in solution it has a higher rotational mobility and thus has an increased likelihood of 
becoming depolarized between the times of excitation and emission. The differences in bocillin’s 
fluorescence anisotropy when bound versus unbound allows for PBP inhibitor binding kinetics to 
be measured using a plate reader. Both compounds displayed similar high Kon values with 
temocillin at 77,000 M-1s-1 and ticarcillin at 21,000 M-1s-1. Temocillin displayed a 20-fold 
difference in its Koff (0.001 s-1) when compared to ticarcillin (Koff < 0.00005 s-1). Due to the fact 
that both temocillin and ticarcillin are covalent inhibitors there are two potential explanations for 
seeing a significant difference in the Koff values but not in the Kon values. It could be that 
temocillin is displaying noncovalent inhibitor kinetics due to it binding in a conformation that is 
catalytically incompatible with the PBP3 active site, thus resulting in the dissociation of the 
compound from the protein before forming a covalent complex within the active site of PBP3. 
Another possibility for why a significant difference in the Koff values is observed but not in the 
Kon values is that PBP3 is displaying low levels β-lactamase activity against temocillin by 
forming an acyl-enzyme complex with the compound and then hydrolyzing the molecule to 
release it from the product complex.  Due to an inability to determine which hypothesis is correct 
further studies were required to determine what the cause of the observed Koff values was.  
3.3.2 Thermostability Studies of PBP3 
 Previous research looking at the binding kinetics of temocillin with E. coli PBP3, 
suggested that either temocillin has weak efficiency in forming an acyl-enzyme complex with 
PBP3 or that it forms an unstable complex with the protein.127 The Kon value observed in the 
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previously discussed fluorescence polarization assay suggests that it is unlikely due to weak 
efficiency in binding to PBP3 and thus it seemed pertinent to probe the stability of the acyl-
enzyme complex of PBP3 with temocillin using circular dichroism in a thermal shift assay. Both 
compounds, temocillin and ticarcillin, were added in molar excess ratios to PBP3 and incubated 
with the protein in order to allow for the covalent product complex to form. After incubation the 
differences in stability of the protein were measured (Figure 4). The melting temperature (Tm) for 
apo PBP3 was observed to be 49.1˚C. By incubating PBP3 with temocillin a Tm of 53.52˚C was 
observed marking a 4.42˚C shift in the melting temperature of the protein; however, when 
incubating the protein with ticarcillin an increase in melting temperature of 7.93˚C was observed 
(Tm =57.03˚C). These results in conjunction with the binding kinetics observed in the 
fluorescence polarization assay suggest that temocillin is forming a destabilized complex with 
PBP3 that results in the dissociation of the compound from the active site. 
3.3.3 Crystallographic Complex Structure Determination with PBP3 
 The biochemical and biophysical data from the previous experiments has suggested that 
due to the destabilizing effects of temocillin binding to PBP3 the compound was dissociating 
from the active site of the protein, but this does not allow for the determination of a mechanism 
by which the deacylation of the compound occurs. In order to develop a mechanistic 
understanding of the deacylation process, x-ray crystallographic studies were performed so that 
complex structures of these compounds with PBP3 could be developed and used to determine 
what molecular interactions were involved in this process. These studies produced complex 
structures of temocillin at 2.1 Å (Figure 5a) and ticarcillin at 1.76 Å (Figure 5b), which provided 
unambiguous, single conformation densities for each of the compounds. Both compounds bind 
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with high similarity in terms of their conformations upon acyl-enzyme complex formation and 
this can be seen upon superimposing the two structures with an RMSD = 0.321. The carboxylate 
moiety, seen on the thiazolidine ring, interacts in the traditional β-lactam fashion with the Ser485 
of conserved PBP K-T/S-G motif. These structures also allowed for the observation of hydrogen 
bond formation between Ser485 and Thr487 and an electrostatic interaction with Lys484. All of 
these contribute to the binding of temocillin and ticarcillin by positioning their β-lactam rings 
within covalent bond formation distance of the catalytic residue of PBP3, Ser294. A continuous 
density can be distinctly seen between the β-C of both compounds and the Ser294 residue of 
PBP3. This unambiguously rejects the hypothesis that temocillin’s binding conformation to 
PBP3 is incompatible for covalent bond formation of the acyl-enzyme complex. In looking 
further at the superimposition of both complex structures, the highly conserved conformations of 
the sidechains can be observed. The hydrophobic pocket formed by PBP3 residues Tyr503, 
Tyr532, and Phe553 is clearly seen interacting with the thiophene rings of both compounds. Both 
compounds also form salt bridges between their carboxylate groups and the residue Arg489. 
Additionally, hydrogen bonds can be seen forming between their carboxylate groups and Tyr409, 
along with another hydrogen bond being formed between the Asn351 of the conserved PBP SXN 
motif and the amide oxygen of both compounds’ sidechains. Temocillin forms an extra hydrogen 
bond with the Asn351 residue by utilizing the oxygen on its 6-α-methoxy group.  
3.3.4 Structure Determination of Temocillin Complexed with CTX-M 
 Compounds, such as cefoxitin, utilize structures of previously identified β-lactam 
antibiotics and have functional groups added to the carbons at positions 6 and 7 of the β-lactam 
ring, in order to prevent the hydrolysis of the β-lactam ring by the β-lactamase enzymes. These 
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functional group additions serve the purpose of displacing or obstructing the catalytic water 
necessary for the deacylation process that is necessary for the proper functioning of serine β-
lactamase enzymes. This allows the antibiotics themselves to act as effective β-lactamase 
inhibitors. In order to confirm this functional role of the 6-α-methoxy group on temocillin, 
further structural studies were carried out by solving a complex crystal structure with CTX-M-14 
wild type, which was able to be determined at a 1.3 Å resolution (Figure 6A). 
 PBPs and serine β-lactamases share a high degree of sequence homology, most likely due 
to an evolutionary linkage between the two enzymes. This is further evidenced by the conserved 
active site motifs seen in both such as the previously mentioned substrate recognition motifs 
SXN and K-T/S-G, along with the catalytic sequence motif SXXK which is required for the 
formation of the acyl-enzyme complex. Where these two enzyme families begin to delineate is 
the presence of the Glu166 in the serine β-lactamases. The Glu166 residue is necessary as it acts 
as the catalytic base by activating the catalytic water that hydrolyzes the β-lactam ring, thus 
severing the acyl-enzyme complex and freeing up the active site of the β-lactamase enzyme to 
degrade additional β-lactam compounds (Figure 2). Given these high similarities in the chemical 
and structural composition of these active sites, the binding conformation of temocillin when in 
complex with CTX-M-14 matching that of the one seen in PBP3 is of no surprise. The 
carboxylate group attached to the thiazolidine ring forms ideal electrostatic interactions with 
Lys234 and Arg276, along with hydrogen bonds to a concerted water and Thr235. The two 
binding conformations differ in the positioning of the temocillin side chain, as in CTX-M-14 this 
sidechain forms hydrogen bonds with Asn104 and Asn132 which pulls it to the opposite side of 
the active site. The most interesting interaction that was observed is the oxygen atom of the 6-α-
methoxy group forming a hydrogen bond with Lys73. The lysine residue acts as the general base 
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in the activation the catalytic Ser70 by abstracting a hydrogen from the Ser130 sidechain 
allowing the protein to form the acyl-enzyme complex with β-lactam rings (Figure 6B). In the 
complex structure, the catalytic water can be observed to have an unobstructed path to the β-C 
that forms the covalent bond with Ser70. This suggests that unlike other C6 and C7 altered β-
lactams, such as cefoxitin, temocillin’s 6-α-methoxy group prevents hydrolytic degradation of 
the compound by preventing the proton transfer carried out by Lys73, rather than through the 
steric hindrance of the catalytic water molecule. 
3.4 Discussion 
3.4.1 The Role of the 6-α-Methoxy Group in β-Lactam Interactions 
The results from the fluorescence polarization assay that showed temocillin having a 
measurable Koff rate seemed to point to PBP3 having β-lactamase activity against temocillin 
given the previous research on the compound found in the literature. PBPs have been shown in 
previous studies to have small amounts of β-lactamase catalytic capabilities.129,130 Additionally, 
PBP3 has proven to be able to degrade some β-lactam compounds, as evidenced by the 
hydrolyzed products of penicillin, azlocillin, and cefoperazone seen in complex with P. 
aeruginosa PBP3.131,132 It is counter intuitive, however, to think that the compound with proven 
evasion of hydrolytic activity in β-lactamases, due to its 6-α-methoxy group, would display an 
increased Koff  rate when compared to its parent compound, which lacks this important functional 
group and has been shown to be susceptible to hydrolytic degradation. If this were the case, it 
would have implied that the hydrolytic water in PBP3’s β-lacatamase activity is approaching 
from a direction that does not get obstructed by the 6-α-methoxy group of the compound like in 
some β-lactamase active sites.  
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The results of the thermal shift assays, however, suggested an alternative hypothesis that 
temocillin is forming a destabilized complex with PBP3 that results in the dissociation of the 
compound from the active site. The crystallographic studies allowed for an understanding of the 
mechanism by which the destabilization was occurring. Although the similarities between the 
two PBP3 complex structures were seen largely throughout both structures, the distinction can be 
made when looking at the 6-α-methoxy group, which gets buried into the active site and points 
towards the Asn351 residue of the highly conserved PBP SXN motif. When looking at the 
ticarcillin complex structure, a hydrogen bond can be seen forming between ticarcillin’s side 
chain amide oxygen and the side chain nitrogen of Asn351. In comparison the temocillin 
complex structure has the same Asn351 side chain nitrogen forming a bifurcated hydrogen bond 
with both the side chain amide oxygen of temocillin and the oxygen of the 6-α-methoxy group.   
The 6-α-methoxy group, however, is a poor hydrogen bond acceptor when compared to the 
amide oxygen. Additionally, this interaction moves temocillin’s amide oxygen 0.4 Å further 
away from Asn351 residue (hydrogen bond distance of 3.2 Å) when compared to the hydrogen 
bond distance seen between ticarcillin and the Asn351 side chain nitrogen which is 2.8 Å in 
length (Figure 7). In competing with the strong amide oxygen hydrogen bond, seen forming with 
Asn351, by introducing a significantly weaker hydrogen bond acceptor and pushing the stronger 
hydrogen bond acceptor further away from the nitrogen donor, the 6-α-methoxy group 
destabilizes the PBP3-temocillin complex. There was no density resolved for a coordinated water 
molecule in the active site of either PBP3 complex structure, which suggests that it is a non-
coordinated water carrying out the catalytic activity necessary to break apart the acyl-enzyme 
complex. This supports the hypothesis that rather than the 6-α-methoxy group acting to protect 
the ligand as thought to be seen in serine β-lacatamase enzymes, the 6-α-methoxy group is 
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simply destabilizing the active site which reduces the entropic requirements for the hydrolysis of 
the product complex and allows for non-coordinated waters to be effective in their ability to 
carry out this reaction. This notion is also supported by the previous study done by Labia et. al 
where temocillin inhibition was restored in a radiolabeled penicillin assay by reducing the 
incubation time and temperature at which the assay was carried out, thus showing the instability 
of the PBP3-temocillin complex.127  
The predicted role of the 6-α-methoxy group in preventing the hydrolysis of temocillin in 
β-lactamases has been understood to be due to a steric hindering of the coordinated water 
molecule, which would prevent the enzyme from degrading the acyl-enzyme complex. However, 
the complex crystal structure of temocillin with CTX-M-14 wild type suggests an alternative 
mechanism for temocillin’s evasion of β-lactamase activity. Given the hydrogen bond formation 
between the 6-α-methoxy group and Lys73 and the unobstructed path of the catalytic water to the 
β-C of temocillin, it would suggest that it is actually carrying out this function by preventing 
Lys73 from acting as a general base, which would prevent the enzyme from hydrolyzing the 
covalent bond it forms with the β-lactam compound and thus irreversibly inhibiting the enzymes 
ability to catalyze further reactions. Additional studies are necessary to support this hypothesis. It 
would be beneficial to obtain an ultra-high resolution CTX-M-14 structure in complex with 
temocillin in which the hydrogen atoms could be resolved. This would allow for the 
determination of whether or not Lys73 was in fact prevented from acting as a general base in the 
catalytic mechanism. 
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3.5 Conclusions 
 Due to the rise of antibiotic resistance and the contribution of P. aeruginosa in this 
emerging health crisis, renewed relevancy for the once ignored antibacterial pharmaceuticals has 
begun to take hold in the clinical setting in an effort to combat bacterial infections that are 
displaying resistance to the current antibiotic regimens. Given its resistance to many β-lactamase 
enzymes including ESBLs and AmpCs, both of which are produced by clinically observed 
strains of P. aeruginosa, temocillin has once again become a desirable therapeutic for use in 
hospitals. However, unlike temocillin’s parents compound ticarcillin, temocillin has shown to 
have weak inhibitory properties when it comes to P. aeruginosa infections. There has been a 
relative lack of exploration in the literature with regards to understanding why temocillin lacks 
clinically useful inhibition of P. aeruginosa infections and has up until this point been thought to 
be related to the expression efflux pumps and poor PBP binding properties. By gathering 
biochemical, biophysical, and structural data support has been gathered for the hypothesis that 
although the 6-α-methoxy group successfully prevents hydrolysis of the β-lactam ring when 
binding to many β-lactamases, it also acts in reducing the stability of the PBP3 product complex, 
which causes a reduction in the entropic requirements for a non-coordinated water to carry out a 
hydrolysis reaction and results in β-lactamase activity being observed when binding to PBP3. 
This resulted in the observed Koff rate and lower thermal stability of the protein seen in the in 
vitro assays. Although there is an exponential increase in the number of potentially confounding 
variables when looking at in vivo data, these results may explain the why there is observed 
weakness in temocillin’s activity against P. aeruginosa, given the critical role PBP3 plays in the 
growth of the organism. While these findings may show a limitation of this particular β-lactams 
usefulness in the clinic, other β-lactam compounds that substitute the 6-α-methoxy side chain 
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with other functional groups that form more favorable interactions with the highly conserved 
Asn351 residue of PBP3 may allow for the preservation of the compound’s ability to resist serine 
β-lactamase activity, while also making it effective in the treatment of P. aeruginosa infections. 
3.6 Experimental Procedures 
3.6.1 Cloning, Expression, and Purification of CTX-M-14 and PBP3 
 CTX-M-14 WT was purified as previously described.133 The recombinant P. aeruginosa 
PBP3 construct (residues 50-579) was cloned into a pET15MHL vector (Addgene). The cloned 
plasmid was then transformed into Rosetta (DE3) PlysS cells and cultured in 2XYT media at 
37˚C until an OD600 of 0.6-0.8 was reached. Induction of protein expression was done overnight 
at 20˚C using 0.5 mM IPTG. The cell culture is then pelleted down using the centrifuge at 5,000 
x g for a total of 10 minutes and resuspended. The resuspended cells are then lysed using a 
sonicator set to an amplitude of 6 with cycles of 10 seconds active and 15 seconds resting for a 
total of 15 minutes. The sample is then put through additional centrifugation and the supernatant 
is collected and loaded onto a HisTrap affinity column and eluted using a linear concentration 
gradient of imidazole into a fractionation tray. Fractions corresponding to the peak were then 
pooled and buffer exchanged in order to remove any imidazole and sodium chloride. The sample 
is then cleaved overnight at 4˚C using TEV protease in order to remove the His-tag. TEV was 
selected as the protease due to the lab having an established protocol for simple purification with 
high yield and the protease having high specificity and fidelity for the given cleavage sites. The 
sample is then again loaded onto the HisTrap affinity column in order to remove the His-tag and 
protease completely from the sample. The flow through is collected, concentrated, and then 
loaded onto a gel-filtration column (HiLoad 16/60 Superdex 75) for additional purification 
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polishing. Fractions corresponding to the expected peak for PBP3 were pooled and concentrated 
to 6 mg/ml. The purity of the protein was assessed using SDS-PAGE and determined to be 
>95%. 
3.6.2 Protein Crystallization 
P. aeruginosa PBP3 crystals were grown in a crystallization buffer conditioning 
containing 20% PEG 3350 and 0.2 M Calcium Acetate using the hanging drop vapor diffusion 
method at 20˚C with a drop ratio of 1:1 for protein (6 mg/ml) to crystallization buffer. In order to 
form complex structures the fully grown PBP3 crystals were transferred to a drop of 
crystallization buffer containing 2mM temocillin or ticarcillin and soaked in solution for 2 hours. 
All crystals were transferred to a cryoprotectant buffer containing 27.5% PEG3350, 0.2 M 
Calcium Acetate, and 15% glycerol prior to flashing freezing with liquid nitrogen. 
CTX-M-14 crystals were obtained by setting up drops with a crystallization buffer 
condition of 1.2 M Potassium Phosphate pH 8.3 and using the hanging drop vapor diffusion 
method at 20°C. The drop was setup with a ratio of 1:1 for protein (10–15 mg/ml) to 
crystallization buffer. In order to form complex structures the fully grown CTX-M-14 crystals 
were transferred to a drop of crystallization buffer containing 2mM temocillin for 2 hours. All 
samples were soaked in a solution of cryoprotectant containing 1.2 M Potassium Phosphate pH 
8.3 and 30% Sucrose, prior to being flash frozen with liquid nitrogen. 
3.6.3 Structure Determination 
 X-ray diffraction data for the PBP3-temocillin complex was collected at the Advanced 
Photon Source (APS) within the Argonne National Laboratories using the 19-BM beamline and 
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processed using the software suite HKL2000.134 Diffraction data for the PBP3-ticarcillin 
complex was also collected at APS on the 19-BM beamline but was processed using the CCP4 
software suite105 with iMOSFLM.103 Diffraction data for CTX-M-14 complexed with temocillin 
was collected at APS using the 22-BM beamline and processed with iMOSFLM. All data was 
further processed using CCP4 with Phaser135 and Molrep104 for the purpose of molecular 
replacement with the previously solved structure of apo-PBP3 (PDB ID: 3PBN) and apo CTX-
M-14 (PDB ID: 1YLT) as the input models. Refmac5107 was utilized for the purpose of further 
refinement of the models and these outputs were visually inspected and refined using Coot.106 
3.6.4 Thermal Shift Assay 
 Changes in secondary structure in response to temperature changes were monitored using 
circular dichroism with a Jasco J-815 CD spectropolarimeter coupled to a Peltier cell holder. A 
sample of PBP3 was diluted down to 2 µg/ml in a buffer of 50 mM sodium phosphate pH 7.0. 
Those samples looking at the effects of temocillin and ticarcillin on protein stability were 
incubated with 15 µM temocillin or ticarcillin for 20 minutes. Melting curves from 40-65°C were 
carried out while measuring at 222 nm within the CD spectra. Data from the experiments was 
analyzed using SigmaPlot (Systat Software, San Jose, CA) with a two-state fitting program. 
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Figure 3.1. Diagram of Enzymatic Activity of PBP Enzymes. The glycosyltransferase 
activity (GT) of PBP enzymes serves to polymerize the N-acetylglucosamine-N-acetyl 
muramic polymers, while the transpeptidase activity (TP) covalently links the D-alanine 
residues of the muramyl pentapeptides to give rise to the highly ordered peptidoglycan 
network. 
Note to Reader 3.1 
Figure 1 in this chapter was previously published 2 by Sauvage & Terrak in 
Antibiotics, 2016 Feb 17;5(1). pii: E12. and has been reproduced with permission (see 
Appendix 1). 
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Figure 3.3. Chemical Structures of Temocillin and Ticarcillin. The only structural 
difference between the two compounds is the presence of a 6-α-methoxy group (red) on the 
β-lactam ring of temocillin. 
Figure 3.2. Diagram of Serine β-Lactamase Catalytic Mechanism. The reaction 
mechanism for the hydrolytic catalysis of β-lactams in serine β-lactamases starts with the 
ground-state Michaelis complex (I), and then continues with the formation of a high-energy 
intermediate transition state (II), before formation of the acyl-enzyme complex (III). The 
process of deacylation then begins when a high-energy intermediate transition state is formed 
after a catalytic water attacks the acyl-enzyme complex (IV), which then results in the release 
of the hydrolyzed β-lactam product and a renewal of the β-lactamase active site (V). 
I II III IV V 
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Figure 3.4. Thermal Shift Assay for P. Aeruginosa PBP3 Incubated with Temocillin 
and Ticarcillin. Apo PBP3 had an observed Tm of 49.1˚C. Incubation of PBP3 with 
ticarcillin (Tm =57.03˚C) displayed a 3.51˚C difference in protein stability when compared 
to the results seen for incubation of PBP3 with temocillin (Tm =53.52˚C). 
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Figure 3.5. Unbiased Fo-Fc map of P. aeruginosa PBP3 Complex Structures. (A) 
PBP3 (green) in complex with temocillin (orange) at 2.1 Å resolution with hydrogen bonds 
(red) formed between temocillin and PBP3. (B) PBP3 (cyan) in complex with ticarcillin 
(magenta) at 1.76 Å resolution with hydrogen bonds (red) formed between ticarcillin and 
PBP3. 
A B 
Figure 3.6. CTX-M-14 WT Complex Structure with Temocillin. (A) Unbiased Fo-Fc map 
of CTX-M-14 β-lactamase (pink) in complex with temocillin (orange) at 1.3 Å resolution. (B) 
Catalytic core of CTX-M-14 in complex with temocillin. The hydrolytic water (magenta) is 
normally activated by Glu 166 (cyan), allowing it to carry out a nucleophilic attack on the 
acyl-enzyme complex. However, the 6-α-methoxy function prevents the formation of the 
deacylation transition state by interfering with proton transfer between Lys73 and Ser70. It 
thus prevents the release of the compound from the acyl-enzyme complex and acts as a 
covalent inhibitor of the β-lactamase enzyme. 
 
A B 
62 
 
  
Figure 3.7. PBP3 Complexes Structure Alignment. Comparison of ligand binding poses 
of temocillin (orange) with ticarcillin (magenta). The 6-α-methoxy group disrupts the 
stronger hydrogen bond formed between temocillin’s amide oxygen and Asn351, 
increasing the hydrogen bond distance of it by 0.4 Å. 
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Chapter 4: 
Structural Analysis of the CCR7 Signaling Molecules 
4.1 Overview 
 CCL19 and CCL21 are both chemokines that bind to the CCR7 chemokine receptor and 
thus play important roles in the trafficking of immune cells, as well as metastatic tumor cells, 
from the bloodstream to the lymphatic system. Both CCL19 and CCL21 have structures that 
were previously solved by NMR.136,137 Expanding on the structural data that is available for these 
proteins x-ray crystal structures for both CCL19 and CCL21 were determined. Using the 
chemical shift mapping data that identifies the critical CCR7 receptor binding sites on both of 
these proteins in conjunction with the protein crystal structures provides the opportunity to carry 
out structure-based drug design with these proteins as the targets and thus develop anti-
metastatic compounds. 
4.2 Introduction 
4.2.1 Chemokines 
Chemokines are a protein family consisting of around 50 small cytokines in humans that 
are generally 8-17 kDa in size and have varying degrees of sequence homology (some as little as 
20%) but all share conserved secondary motifs and a conserved tertiary fold.138-141 These proteins 
are grouped  into 4 subfamilies based on the spacing of their conserved cysteine residues (CC, 
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CXC, CX3C, and XC).142 They play a critical role in the directing of homeostatic and 
proinflammatory immune responses by binding with high-affinity and activating their cognate 
seven transmembrane G-protein coupled receptors (GPCRs) that are responsible for inducing cell 
migration along a gradient of increasing chemokine concentration.143,144  
4.2.2 Chemokines and Cancer 
Chemokines primarily function as signaling molecules for immune cell homing and 
migration; hence, they also pose a pivotal role in inflammation, which is now known to be 
critical to the progression and spread of many different types of cancer.145-148 Different types of 
cancer take advantage of the chemokine receptor signaling axes by inducing the primary tumor 
cells to express the receptors, in order to cause tumor cell migration.149 In addition to playing a 
crucial role in metastasis chemokines also appears to be critical to tumor growth and progression 
through their recruitment of proinflammatory leukocytes (macrophages, neutrophils, fibroblasts, 
and mesenchymal stem cells), to the primary tumor site. The leukocytes then modulate the 
microenvironment for optimal tumor growth.139,150,151 Individual microenvironments reflect the 
biochemical space created as a result of leukocytes releasing various proteases, growth factors, 
angiogenic factors, and immunosuppressive cytokines; the combination of signaling molecules 
then complement tumor cell proliferation, invasion of the extracellular matrix, and eventually 
angiogenesis.139,150,151 It is because of the chemokine’s crucial involvement in the development 
and progression of the cancer disease state that chemokines have become of particular interest to 
researchers. 
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4.2.2.1 CCR7 Signaling Axis and Disease 
The homeostatic chemokine receptor CCR7 plays a role in the trafficking of lymphocytes 
cells across high endothelial venules.152,153 CCR7 is activated by both CCL19 and CCL21, the 
two cognate chemokines of the receptor; however, each chemokine induces differential effects 
and these effects also vary across the different cell types that express the CCR7 receptor.154 For 
example, white blood cell cancer studies conducted by Lopez-Giral et al. (2004) and Harris et al. 
(1994) have shown that the CCR7 signaling axis plays a particularly significant part in the 
metastasis of lymphomas and leukemias by causing these tumors to spread to the lymph nodes 
and secondary lymphoid organs.155,156 CCL19 appears to play a pivotal role in the metastasis of 
T-cell leukemias when invading the central nervous system (CNS).157,158 In addition to playing a 
role in the metastasis of certain cancers, CCL19 also induces signaling of the CCR7 receptor 
when HIV-1 infects resting T-cells, which results in a latent infection due to the prevention of 
reproduction of the viral genome but increase in the viral DNA being localized to the nucleus 
and integrated into the host cell genome.159,160 Prevention of this latent infection would be of 
great interest for therapeutics since this capability of the virus is one of the primary mechanisms 
by which it escapes eradication by the currently available antiretroviral therapies for treatment of 
HIV-1.159-161 Furthermore, it is CCL21 that acts as the primary signaling molecule for the 
metastatic patterns seen in many different types of cancer (e.g., skin, colon, cervical, and breast 
cancers). 162-166 Additionally, some cancers overexpress CCL21 in order to evade host immune 
responses and create lymphoid-like microenvironments that are ideal for tumor growth and 
progression.167  
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4.2.3 Structure and Function Comparison of CCL19 and CCL21 
 In addition to both playing a role in cancer metastasis, both CCL19 and CCL21 share the 
canonical chemokine tertiary fold, the same spacing of the conserved cysteine residues, and have 
a sequence identity of 35% (Figure 4.1).168 However, CCL21 (M.W.= 14.6 kDa) is significantly 
larger than CCL19 (M.W.=10.9 kDa),169 which is due to the extended C-terminus seen on 
CCL21.168 The 40 amino acid C-terminal tail has proven to be essential for CCL21’s ability to 
bind the glycosaminoglycan heparin sulfate, and thus plays a vital role in CCL21’s functionality 
as an adhesive motility protein. This role also in part explains the differential responses seen 
when the two chemokines (CCL19 and CCL21) bind to CCR7, despite having similar binding 
affinities for the receptor.154,170 Additionally, CCL21 is unique in that it has a total of six cysteine 
residues instead of the typical four, like most other chemokines.168 Sequence analysis predicts 
the existence three disulphide bonds for this protein but only two have been established in the 
literature, due to the difficulty in solving a structure of the wild type form with its highly flexible 
C-terminal tail.136,171 Further explanation for the differential functionality of CCL19 and CCL21 
is that they both bind to other receptors. CCL19 binds to the atypical chemokine receptor 
ACKR4, which allows for stromal cells to scavenge the CCR7 signaling axis during skin 
inflammation.172 CCL21 is capable of binding to CXCR3 where it plays a role in regulating Th1 
immune responses.173,174 The other way by which the body maintains functional differences for 
these two proteins is through altered expression and localization of the proteins throughout 
various tissue regions.175,176 
4.2.4 Receptor Binding of the Chemokines and Sulfotyrosine Recognition 
Chemokines and corresponding receptors form protein-protein interactions which follow 
a general mechanism of receptor activation.177 The chemokine is initially recognized by the 
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extracellular, flexible N-terminal tail domain of the receptor. After recognition, the flexible N-
terminus of the chemokine gets inserted into the transmembrane channel of the receptor and 
binds to this portion of the protein. This second binding event triggers receptor internalization 
and intracellular downstream signaling cascades such as calcium influx, all eventually resulting 
in a chemotactic response by the cell expressing these receptors (Figure 4.2).177-179 Studies done 
by Farzan et al. (2002) and Seibert & Sakmar (2008) have shown that sulfation of the tyrosine 
residues located on the N-terminus of chemokine receptors are essential for binding to their 
cognate chemokines by imparting a large amount of the affinity involved in these 
interactions.180,181 Additionally, this specific functional significance of tyrosine sulfation has 
been shown to be conserved across a multitude of chemokines.182-184 Veldkamp et al. (2008) 
showed that an equivalent sulfotyrosine-binding pocket appears to be conserved across the 
chemokine superfamily.183 Traditionally protein-protein interaction interfaces have been 
considered poor candidates for small molecule drug discovery due to their large, shallow, and 
solvent exposed binding sites.185,186 However, these sulfotyrosine recognition sites have proven 
to be exploitable for designing inhibitors that block the binding of the chemokine for the receptor 
due to the high amount of affinity they impart to this interaction.187,188 
4.3 Results 
4.3.1 Solving the Crystal Structure of CCL19 
 As previously mentioned, crystallographic protein complex structures are invaluable to 
structure based drug design efforts as they afford the ability to determine what specific molecular 
interactions are involved in the binding event of small molecules to their target protein. 
Additionally, these structures tend to have higher resolution than other structural techniques and 
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thus provide more accurate results when carrying out molecular docking experiments. Thus 
crystal structures for CCL19 and CCL21 were solved in order to obtain this information. 
 CCL19 was crystallized with a P43 space group and a unit cell length of a=87.31 Å, 
b=87.31 Å, c=143.49 Å, and unit cell angles of α=90°, β=90°, and γ=90° (Table 4.1). The x-ray 
crystal structure was resolved at a resolution of 2.5 Å. The asymmetric unit is made up of 18 
protein monomers but the observed symmetry does not appear to be biologically relevant as none 
of the orientations taken on by the protein monomers to form dimer interfaces match with the 
previously solved CC chemokine dimers.189,190 There is no significant variation in the 
conformations of the different monomers which can be observed upon superimpostion of all the 
monomers onto one another. Upon superimposing all the monomers onto monomer N, the 
monomer with the lowest B-factor (25.53 Å2), the average RMSD is 0.4 Å, aligning an average 
of 383 atoms. The low average RMSD value confirms the visual analysis of the superimposition. 
The only observed conformational variation between the monomers lies in the flexible N-
terminus of the protein. The secondary and tertiary structure observed in all the monomers of the 
crystal structure correspond to the previously solved NMR structure of CCL19.137 Conserved 
cysteines (residues 8 and 9) form disulfide bonds with the conserved Cys34 and Cys50. The N-
terminal tail is followed by the N-loop (Cys9-Val17) of the protein. The N-loop connects to the 
β1 strand (Arg18-Lys23), which is joined to the β2 strand (Ala33-Thr37) via the 30’s loop 
(Lys24-Pro32). In between the β2 strand and the β3 strand (Gly41-Ala46) lies the small 40’s 
loop (Thr38-Gly41). The third β strand is connected to the C-terminal alpha helix (Pro51-Thr63) 
with the protein ending in the truncated C-terminus.    
 
 
69 
 
4.3.2 Solving the Crystal Structure of CCL21  
CCL21 was crystallized with a P21 space group and a unit cell length of a=65.75 Å, 
b=58.24 Å, c=66.0/5 Å and unit cell angles of α=90°, β=119.94°, and γ=90° (Table 4.1). The x-
ray crystal structure was resolved at a resolution of 1.9 Å, which yielded novel structural 
information not afforded by the previously determined NMR structure. In addition, this further 
enhances the literature with regards to the critical molecular interactions that play a role in the 
structure and function of CCL21. The asymmetric unit is made up of six monomers and has a 6-
fold pseudo-symmetry (Figure 4.3A). This symmetry does not appear to be biologically relevant, 
like in CCL19, as none of the dimer interfaces formed between the various monomers 
corresponds to previously determined dimeric CC chemokine structures; it has been previously 
established by past research that CCL21 is monomeric.136,190,191 The average B-factor of each 
monomer ranges from 22.6 to 24.3. When superimposing all of the monomers onto monomer B, 
the monomer with the lowest B-factor (22.6 Å2), the observed average RMSD is 0.2 Å, aligning 
an average of 417 atoms (Figure 4.3B). This shows there is little variation between the individual 
monomers within the asymmetric unit and this can be seen upon visual inspection as well of the 
superimposition. The primary source of conformational variation is observed in the 30’s loop, 
composed of residues Glu29 through Pro37, with some mild conformational variation in the 40’s 
loop (residues Arg44-Glu50) and N-loop (Cys9-Val22) as well. As expected there is also a tiny 
amount of variation in the truncated but still flexible C-terminus, as well as in the N-terminus. 
The secondary and tertiary structure of each monomer matches the NMR structure previously 
determined in the literature with two adjacent cysteines (Cys8 and Cys9). Together they form 
disulphide bonds with the other conserved cysteines (Cys34 and Cys52). The disulfide bonds are 
followed by the N-loop, then the three β-strands (β1 [residues Val22-Gln28], β2 [residues Ala38-
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Pro43], β3 [residues Leu51-Ala53]), ultimately forming an anti-parallel β-sheet. In between the 
β1 and β2 strand is the 30’s loop made up of residues Glu29-Pro37; in between the β2 and β3 
strand is the 40’s loop. The third β-strand is then followed by a ten amino acid long α-helix 
(residues Glu57 through Leu67) and the protein ends with the truncated but still flexible C-
terminal tail (Figure 4.3C). 
4.3.3 Determining the Sulfotyrosine Recognition Sites on CCL21 
 It was first sought to confirm that, like other chemokine receptors, sulfation of the N-
terminal tyrosine residues imparted CCR7 with an increased binding affinity for CCL21. Upon 
confirming this the next step was the identification of the potential binding sites that could be 
used to carry out structure-based drug discovery, so it needed to be established where the CCR7 
sulfotyrosine recognition hotspots were located on CCL21. Previous research has been published 
showing that a unsulfated N-terminal fragment peptide of the CCR7 receptor (residues 1-30) 
bound to full length CCL21 using a 2D 1H-15N HSQC assay which allowed for the analysis of 
chemical shift perturbations in the 1H-15N spectrum of CCL21.192 By mapping the chemical 
shifts onto the structure of CCL21, the residues that exhibited specific binding with the titrated 
molecule were determined. This assay showed that the receptor binds to the N-loop, the 40’s 
loop, and the β3-strand of CCL21 with a Kd value of 150 ± 30 µM (Figure 4.4B).136 The 2D 1H-
15N HSQC assay was repeated with a similar CCR7 synthetic fragment peptide (residues 5-30), 
but this fragment had sulfated tyrosine residues at positions 8 and 17; this resulted in over a 
2000-fold increase in the estimated binding affinity, with the Kd value being 72 nM (Figure 
4.4B).192 The 2D 1H-15N HSQC assay established that similar to other chemokines and their 
cognate receptors, the affinity of CCL21 for CCR7 is greatly affected by the sulfation of the N-
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terminal tyrosines. However, in order to determine specifically where these high affinity hotspots 
were on CCL21 it was necessary to carry out the same 2D 1H-15N HSQC assay again. 
The subsequent titration was carried out with small CCR7 fragment peptides containing 
the two separate sulfotyrosine residues (sY8 and sY17) found on the N-terminus of the receptor. 
When titrating with the sY17 containing fragment (CCR7 residues 11-30) the significant 
chemical shifts outlined a binding pocket which was composed of the N-loop, 40’s loop, and β3-
strand, giving an estimated binding affinity with a Kd of 480 ± 80 µM (Figure 4.4).192 These 
residues corresponded to what was found in the previously published data with the single 
unsulfated CCR7 N-terminal fragment peptide and the conserved sulfotyrosine binding pocket 
found on other chemokines.183,193 However, when titrating with the sY8 containing fragment 
(CCR7 residues 5-11) significant chemical shifts outlined a novel binding pocket between the N-
loop and the α-helix of CCL21. This resulted in a much higher estimated binding affinity (Kd = 
150 ± 40 µM) when compared to the sY17 binding pocket (Figure 4.4).192  
Upon having established that sulfation was indeed critical for the binding affinity of 
CCL21 to CCR7, the next logical step was to probe if sulfation potentially had any effect on 
specificity for the receptor as well. This was accomplished by carrying out the same chemical 
shift perturbation assay with the same CCR7 N-terminal peptide fragments but lacking sulfation 
on the tyrosine residues 8 and 17. The results of this showed that the same residues are perturbed 
upon titration with the unsulfated peptides but as predicted a significant decrease in binding 
affinity estimates are seen for both fragments (Figure 4.4), suggesting that sulfation does not play 
a role in binding specificity.192 Comprehensively, the results from the NMR perturbation assays 
support the current literature on the existence of conserved sulfotyrosine recognition sites across 
the chemokine superfamily, along with the understanding that sulfation of the CCR7 N-terminal 
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tyrosine residues contributes heavily to the binding affinity, but not the binding site specificity, 
seen for CCL21 towards its cognate receptor. 
4.3.4 Structure Based Drug Design Against CCL21 
 Using the identification of two discreet sulfotyrosine recognition sites on CCL21 
molecular docking experiments were carried out in order to screen for compounds that could 
potentially bind to the chemokine. The first target was the sY8 site given its significantly higher 
affinity contribution towards the binding free energy of the CCR7 receptor. Multiple iterations of 
docking were carried out against this site using DOCK 3.5.4 and the ZINC database as the 
compound library. Initially the conformational space being sampled in the docking experiments 
was determined by selecting target residues. These target residues were previously shown in the 
NMR perturbation studies to interact with the CCR7 fragments and thus used to generate an 
outline of the pocket of interest. After the initial round of docking the predicted ligand poses 
were visually inspected, and the top compounds were selected and then ordered for testing to 
determine if they would actually bind to CCL21. The top three compounds predicted to be the 
strongest binders based on their binding pose from this initial round were then used in additional 
rounds of docking in order to determine the conformational space being sampled and bias the 
results towards these scaffolds with the desired chemotypes that took advantage of the chemical 
space in the binding site. The docking results were visually analyzed once again, and the top 
compounds were selected and ordered for testing. 
 NMR 2D 1H-15N HSQC perturbation assays were carried out using radiolabeled CCL21 
and titrating the sample along with dissolved compounds that were ordered from the docking 
experiments. Five compounds were found to bind to CCL21, all with affinities in the mM range 
(Table 4.2). The chemical shifts were mapped onto a model of CCL21 to determine where the 
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compounds were binding and confirm the interactions were localized to the target binding sites 
on the chemokine. All the compounds that were found to bind to CCL21 in the NMR titration 
assays showed similar chemical shift data, and all with residues that were found to be within the 
predicted sY8 binding pocket. The compound exhibiting the highest affinity for CCL21 was 
compound BV15-017, which showed chemical shift perturbations with residues Lys16, Ala19, 
Val21, and Leu63; these four residues are located on the N-loop or α-helix portion of CCL21. 
Compounds BV15-019 and BV15-020 showed chemical shift perturbations with residues Lys16 
and Val21; both residues are found exclusively along the N-loop of CCL21. Compound BV15-
012 was found to interact with Lys16 and Val21, as well as with Thr70 which is found on the C-
terminal tail of CCL21. More specifically, Thr70 is located at the very end of the α-helix portion 
of the protein which makes up the far end of the sY8 pocket. Similarly, the compound BV15-015 
was found to interact with Thr70, but also Ile17 a residue also located the N-loop of CCL21. 
This data suggested that the BV15-012 and BV15-015 compounds when binding to CCL21, 
spanned the entirety of the predicted sY8 binding pocket, but also showed the weakest estimated 
binding affinities for the protein (Table 4.2). 
4.4 Discussion 
4.4.1 Significance of the C-terminal Tail for CCL21 
 The literature has shown that the C-terminus of CCL21 is critical to the chemokine’s 
ability to interact with the glycosaminoglycans (GAGs) found in the extracellular matrix, as 
truncation of this portion of the protein has resulted in a reduction for its affinity towards 
GAGs.194,195 It has also been shown that the cleavage of the C-terminus occurs in vivo via 
protease catalysis in order to establish a soluble CCL21 chemokine gradient, as opposed to a 
stationary one.170,196 This suggests that a C-terminal truncation to the chemokine is biologically 
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relevant. Further evidence for the biological relevancy of this truncation has been seen in the 
research that suggests the C-terminal portion of CCL21 can perform an auto-inhibitory function 
for the chemokine.197 It has been shown that post-translational modification of the CCR7 
receptor via the addition of polysialic acid (PSA) in dendritic cells greatly enhances the binding 
affinity of the receptor for the C-terminal portion of CCL21 and thus increases CCR7 activation 
and the resultant chemotactic response in the dendritic cells.198-200  This evidence suggests that 
the GAGs that are imparting this inhibitory action when bound to CCL21, while PSA is simply 
serving to interrupt this interaction between the chemokine and the extracellular matrix.195 
However, the increase in binding affinity seen for the PSA-altered CCR7 receptor has also been 
reported to occur in the absence of GAGs, suggesting that PSA acts to interrupt the auto-
inhibitory state of full length CCL21.199 Furthermore, PSA cannot be acting strictly as a co-
activator of CCR7 for CCL21, because C-terminal truncated CCL21 can still activate the CCR7 
receptor regardless of whether the PSA modification on the receptor is present or not.199 
Altogether, the findings from these studies suggest that the C-terminal domain of CCL21 acts to 
engage an auto-inhibitory mechanism for the chemokine.  
 Variation in the conformational state of the sY17 recognition site due to the presence of 
the C-terminal tail can be noted by comparing the CCL21 crystal structure with the previously 
determined NMR structure of CCL21 (PDB ID: 24LN). In the crystal structure the partially 
intact C-terminal tail appears to occlude the surface of the protein that has been identified as 
having a role in recognition of the CCR7 receptor (Figure 4.5). Within the literature there is also 
an NMR study that determined the residues on CCL21 that interact with the C-terminal tail of the 
chemokine by mapping the chemical shift perturbations observed when comparing a truncated 
form of the protein that lacked the C-terminal tail (CCL21 1-79) and a non-truncated construct of 
75 
 
the protein (CCL21 1-111).199 Additionally, it can be seen in the crystal structure that the C-
terminal tail is oriented towards the N-loop of the protein. This orientation suggests that the C-
terminal tail may be interacting with the N-loop and neighboring residues; thus, altering their 
conformational states and influencing CCL21’s ability to interact with the CCR7 receptor 
(Figure 4.5). The argument could be made that the variation in the N-loop’s conformational state 
is the result of a crystal packing artifact, but when the crystal structure of CCL21 is compared to 
the previously solved crystal structure of the related chemokine CCL18 the probability of this 
being the case diminishes. CCL18 does not have an elongated C-terminus and thus closely 
resembles the truncated form of CCL21 seen in our crystal structure.189 Unlike many of the 
chemokines in the CC subfamily, both CCL18 and CCL21 function as monomers in addition to 
their display of high similarity in their secondary and tertiary structure (Figure 4.1). However, 
the CCL18 structure reveals completely different interactions at the crystal packing interface 
compared to those seen in the truncated CCL21 structure. It is unlikely that these two highly 
similar proteins would adopt such similar structural conformations as the result of profoundly 
different crystal packing interfaces. In addition to this, when comparing the structure of our 
truncated CCL21 to the structure of our truncated CCL19, which also lacks an elongated C-
terminal tail, there is high similarity in the conformation of the N-loops (Figure 4.1). These 
structural comparisons lead to the conclusion that the conformation of the C-terminal tail in our 
crystal structure is likely to have biological relevance to the function of CCL21. It is worth 
mentioning that our data does not exclude the possibility that the C-terminal tail of CCL21 is 
altering the function of the chemokine by having direct interactions with CCR7 and thus 
additional studies are needed to explore this potential mechanism of action. 
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4.4.2 Significance of the N-terminal Tail for CCL19 
 The prevailing thought on what the primary functional significance of the flexible N-
terminal tail of chemokines is that they are solely responsible for stabilizing the active form of 
the chemokine receptors through weak interactions with the trans-membrane domain of the 
receptor.201-204 This notion has been supported by many studies carried out looking at the effects 
of truncating the N-terminus of different chemokines, which all showed that such alterations 
affected receptor activation but little to no effect on the binding affinity of these proteins for their 
cognate receptors.177,203,205-209 However, uniquely the eight N-terminal residues of CCL19 were 
shown to not only effect receptor activation but also have a role in the high affinity binding 
towards the receptor.210 Based on the results of these previous truncation studies it would be 
reasonable to think the N-terminal residues were forming direct interactions with the receptor in 
order to contribute to the binding affinity of the CCL19 for CCR7, as these truncations directly 
resulted in significantly lower binding affinities.210 However, later research using NMR 
perturbation assays that titrated receptor fragments with radiolabeled CCL19 did not indicate that 
these residues played any part in directly interacting with the CCR7 receptor.137 These NMR 
perturbation assays indicated that the N-loop, β-3 strand, and α-helix of CCL19 were the 
segments of the protein that interacted with the receptor directly.137  
When superimposing the crystal structure of CCL19 onto the previously solved NMR 
structure of the protein the greatest variation in the conformational state of the protein, due to the 
presence of the N-terminal tail, can be seen in the N-loop region of the protein (Figure 4.6). In 
the NMR structure the N-terminal tail can be seen bending back and orienting towards the N-
loop and interacting with this segment of the protein. Thus, these interactions appear to alter the 
binding affinity for the receptor by inducing a conformational state in the N-loop region that is 
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compatible with receptor binding, rather than the N-terminal residues interacting directly with 
the receptor themselves. The truncated version of the CCL19 protein (residues 7-70) seen in the 
crystal structure corresponds to the truncated CCL19 seen in the GTP-γS binding and chemotaxis 
assays that displayed partial agonist activity, thus it seems that this conformational state must be 
responsible for this observed reduction in binding affinity and chemotactic response.210 This is a 
logical conclusion, especially when considering the results from the previous CCL19 truncation 
binding assays and NMR perturbation studies, and represents yet another potential biological 
mechanism for increasing the precision of chemotactic responses. Again, it could be argued that 
this N-loop conformation could be the result of a crystal packing artifact; however, given the 
previous comparison of the CCL18, CCL19, and CCL21 crystal structures and the three different 
unique crystal packing interfaces of these proteins, it is unlikely that this conformation would be 
the result protein crystal packing (Figure 4.1). 
4.4.3 Targeting CCL21 with Structure-Based Drug Design 
 Chemokines and their receptors have been implicated in a host of disease states and thus 
have become of great interest to researchers for their potential as therapeutic targets.211,212 Drug 
discovery efforts against this signaling axis have remained predominantely focused on targeting 
the chemokine receptors due to difficulty in targeting protein-protein interfaces with small 
molecules.185,213 Even so, due to the particular mechanism of chemokine-receptor recognition 
using sulfotyrosines for affinity enhancement, it has been shown that these small proteins can in 
fact serve as good targets for small molecule inhibitor discovery, as previous efforts targeting 
CXCL12 have shown.187,188 Given the identification of the this conserved mechanism across 
chemokines and the impact it has on the affinity of the protein for the receptor it was shown to be 
feasible to go forward with a structure-based drug design efforts against CCL21. Initial efforts in 
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using the CCL21 crystal structure to carry out molecular docking studies served as a proof of this 
concept by allowing for identification of five novel ligands that displayed the ability to bind to 
the target protein with reasonable affinity for initial hit compounds. These compounds were 
confirmed to be binding at the sY8 recognition target site through the use of 2D NMR 15N-1H 
HSQC assays. Further improvements to binding affinity of these initial hit compounds is 
necessary, but this will require additional structural information through the capturing of 
complex crystal structures with these compounds. Determining these structures will allow for the 
rational addition of enhanced functional groups to the current compound scaffolds. Future 
studies should aim to improve the interaction with the receptor, targeting the sY17 recognition 
site despite its lower affinity contributions, as identification of hit compounds here could be used 
to link with compounds identified to bind at the sY8 site. This would offer the chance to create 
larger compounds with ultra-high affinity and specificity for CCL21. 
4.5 Conclusions 
In solving the crystal structure of truncated CCL21 and CCL19 alternative N-loop 
conformations were identified. Both appear to play a crucial role in receptor recognition, but 
neither of these alternative conformations were observable in the previously published NMR 
structures.136,137 The CCL19 structure helps resolve the question left by the previously carried out 
CCR7 binding affinity, chemotaxis, and NMR perturbation studies and also suggests a novel 
mechanism by which the N-terminal tail of CCL19 serves to regulate the signaling of the protein. 
The CCL21 structure also further elucidated potential roles the C-terminal tail of CCL21 may 
play in the biological functioning of the protein, along with an explanation of the potential 
mechanism of action by which it carries out its auto-inhibitory function. Additionally, the 
identification of two discreet sulfotyrosine recognition sites on CCL21 provided important 
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structural information that can be utilized in the targeting of the chemokine for small molecule 
inhibitor discovery efforts. This was proven by successful identification of the five hit 
compounds that showed reasonable affinity for initial hits; these compounds represent the only 
currently reported CCL21-specific small molecule inhibitors and serve as an ideal starting point 
for further structure-based drug discovery efforts. Furthermore, the results support the hypothesis 
that it is possible to target a multitude of the chemokine signaling proteins with small molecules 
by identifying these conserved sulfotyrosine recognition sites and hopefully will lead to 
additional efforts in designing new drugs for the range of diseases this family of proteins has 
been implicated in.      
4.6 Experimental Procedures 
4.6.1 Purification of CCL21 
The C-terminal truncated sequence of CCL21 (residues 1-79) was inserted into a pQE30 
vector (Qiagen) along with a SUMO tag (His6-SMT3) and then transformed into competent 
BL21 (pREP4) E. coli cells. The cells were then cultured in LB media (50 ml) and incubated 
overnight at 37˚C. 10 ml of the culture is then diluted into 1L culture of LB media containing 25 
µg/ml of kanamycin and 50 µg/ml of ampicillin and incubated at a temperature of 37˚C until an 
OD600 of 1.0 is reached. Expression of the vector was induced with 500 µM IPTG and the culture 
is incubated for another 4 hours. The cell culture is then pelleted down using the centrifuge at 
5,000 x g for a total of 10 minutes and resuspended in 20 ml of 20 mM Tris pH 8.0, 300 mM 
NaCl, 20 mM imidazole, 0.1% β-mercaptoethanol, and Pierce protease inhibitor tablet (Thermo 
Scientific). The resuspended cells are then lysed using a sonicator set to an amplitude of 6 with 
cycles of 10 seconds active and 15 seconds resting for a total of 15 minutes. The sample is then 
collected using additional centrifugation at 40,000 x g for a total of 40 minutes. The protein is 
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expressed in inclusion bodies and thus needs to be resuspended in 20 ml of a denaturing buffer 
composed of 20 mM Tris pH 8.0, 6 M Guanidine HCl, 300 mM NaCl, and 10 mM imidazole and 
incubated in a hot water bath of 37˚C for 1 hour, while being occasionally shaken. The sample is 
then centrifuged again at 40,000 x g for 40 minutes and the supernatant is collected and filtered 
using a 0.2 µm filter in order to prepare it for high-performance liquid chromatography (HPLC). 
The sample is loaded to the HisTrap Affinity column at a rate of 1 ml/minute and eluted in a 
single step using a buffer containing 100 mM Sodium Acetate pH 4.5, 6 M Guanidine HCl, 300 
mM NaCl. The sample is then dropwise diluted in 200 ml of refolding buffer containing 100 mM 
Tris pH 8.0, 10 mM Cysteine (reduced), and 0.5 mM Cystine (Oxidized). The sample is then 
allowed refold overnight at 4˚C. The sample is then filtered, concentrated, and diluted into a 
cleavage buffer made of 20 mM Tris pH 8.0, 150 mM NaCl, and 10% Glycerol. The SUMO tag 
is then cleaved off through proteolysis using 2.4 mg of ULP1 and incubated overnight at 30˚C. 
ULP1 was selected as the protease due to the protease having high specificity and fidelity for the 
given SUMO tag. The sample is then filtered in order to remove any precipitate formed during 
the cleavage process. Then the sample is again concentrated and buffer exchanged to 20 mM Tris 
pH 8.0, 300 mM NaCl and 40 mM Imidazole in order to prepare for additional HPLC runs. The 
sample is then run through the HisTrap affinity column again at a rate of 1 ml/minute in order to 
remove the SUMO tag and protease. The sample is collected and then further concentrated and 
loaded onto a gel filtration column (HiLoad 16/60 Superdex 75 column) and eluted using a 
buffer containing 20 mM Tris pH 7.0 and 300 mM NaCl. The sodium chloride is critical to 
getting a protein yield, due to the ability of CCL21 to bind glycosaminoglycans even in its 
truncated form. The sodium chloride prevents CCL21 from interacting with the generally inert 
matrix of the gel filtration column. After collecting the sample from the gel filtration column it is 
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tested for purity using an SDS-PAGE gel. This resulted in a 10.4 mg/ml yield of CCL21 with a 
purity that was greater than 95%. 
4.6.2 Purification of CCL19 
The C-terminal truncated sequence of CCL21 (residues 7-70) was inserted into a pQE30 
vector (Qiagen) along with a SUMO tag (His6-SMT3) and then transformed into competent 
BL21 (pREP4) E. coli cells. The cells were then cultured in LB media (50 ml) and incubated 
overnight. 10 ml of the culture is then diluted into 1L culture of LB media containing 25 µg/ml 
of kanamycin and 50 µg/ml of ampicillin and incubated at a temperature of 37˚C until an OD600 
of 1.0 is reached. Expression of the vector is induced with 500 µM IPTG and the culture is 
incubated for another 4 hours. The cell culture is then pelleted down using the centrifuge at 5,000 
x g for a total of 10 minutes and resuspended in 20 ml of 20 mM Tris pH 8.0, 300 mM NaCl, 20 
mM imidazole, 0.1% β-mercaptoethanol, and Pierce protease inhibitor tablet (Thermo 
Scientific). The resuspended cells are then lysed using a sonicator set to an amplitude of 6 with 
cycles of 10 seconds active and 15 seconds resting for a total of 15 minutes. The sample is then 
collected using additional centrifugation at 40,000 x g for a total of 40 minutes. The protein is 
expressed in inclusion bodies and thus needs to be resuspended in 20 ml of a denaturing buffer 
composed of 20 mM Tris pH 8.0, 6 M Guanidine HCl, 300 mM NaCl, and 10 mM imidazole and 
incubated in a hot water bath of 37˚C for 1 hour, while being occasionally shaken. The sample is 
then centrifuged again at 40,000 x g for 40 minutes and the supernatant is collected and filtered 
using a 0.2 µm filter in order to prepare it for high-performance liquid chromatography (HPLC). 
The sample is loaded to the HisTrap Affinity column at a rate of 1 ml/minute and eluted in a 
single step using a buffer containing 100 mM Sodium Acetate pH 4.5, 6 M Guanidine HCl, 300 
mM NaCl. The sample is then dropwise diluted in 200 ml of refolding buffer containing 100 mM 
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Tris pH 8.0, 10 mM Cysteine (reduced), and 0.5 mM Cystine (Oxidized). The sample is then 
allowed refold overnight at 4˚C. The sample is then filtered, concentrated, and diluted into a 
cleavage buffer made of 20 mM Tris pH 8.0, 150 mM NaCl, and 10% Glycerol. The SUMO tag 
is then cleaved off through proteolysis using 2.4 mg of ULP1 and incubated overnight at 30˚C. 
ULP1 was selected as the protease due to the protease having high specificity and fidelity for the 
given SUMO tag. The sample is then filtered in order to remove any precipitate formed during 
the cleavage process. Then the sample is again concentrated and buffer exchanged to 20 mM Tris 
pH 8.0, 300 mM NaCl and 40 mM Imidazole in order to prepare for additional HPLC runs. The 
sample is then run through the HisTrap affinity column again at a rate of 1 ml/minute in order to 
remove the SUMO tag and protease. The sample is collected and then further concentrated and 
loaded onto a gel filtration column (HiLoad 16/60 Superdex 75 column) and eluted using a 
buffer containing 20 mM Tris pH 8.0, 150 mM NaCl, and 10% Glycerol. After collecting the 
sample from the gel filtration column it is tested for purity using an SDS-PAGE gel. This 
resulted in a 13.3 mg/ml yield of CCL21 with a purity that was greater than 95%. 
4.6.3 Crystallization Screening of CCL21 
Taking the now purified CCL21 protein screening began for crystallization conditions 
using Qiagen JCSG I-IV and AmSO4 suites, along with Hampton Crystal Screens I and II and 
placing them on the Crystal Phoenix robot, which was used to dispense 0.2 µl of protein solution 
at 10 mg/ml, into a sitting drop screening tray containing 0.2 µl of crystallization buffer solution 
in each well. These trays were stored at 20˚C in our crystallization incubator. Crystals appeared 
in the well containing a buffer condition of 3.0 M ammonium sulfate and 1% MPD. This 
condition was then scaled up using hanging drop crystallization trays and optimized by altering 
the crystallization buffer condition to 2.7 M ammonium sulfate and 0.5% MPD. Additionally, the 
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drop ratio was altered to 2 µl of protein for every 1 µl of crystallization buffer solution. In order 
to prepare the crystals for x-ray diffraction they are then soaked in a cryo-protectant solution 
containing 2.7 M ammonium sulfate, 0.5% MPD, and 25% glycerol. 
4.6.4 Crystallization Screening of CCL19 
Taking the now purified CCL19 protein screening began for crystallization conditions 
using Qiagen MPD and AmSO4 suites, Jena Bioscience JCSG Plus and PACT screens, and the 
Rigaku Berkley and Top96 screens and placing them on the Crystal Phoenix robot, which was 
used to dispense 0.2 µl of protein solution at 13 mg/ml, into a sitting drop screening tray 
containing 0.2 µl of crystallization buffer solution in each well. These trays were stored at 20˚C 
in our crystallization incubator. Crystals appeared in the well containing a buffer condition of 
20% PEG3350 and 0.2 M sodium nitrate. This condition was then scaled up using hanging drop 
crystallization trays and optimized by altering the crystallization buffer condition to 20% 
PEG3350 and 0.2 M sodium nitrate with a final pH of 5.5. Additionally, the drop ratio was 
altered to 2 µl of protein for every 2 µl of crystallization buffer solution. In order to prepare the 
crystals for x-ray diffraction they are then soaked in a cryo-protectant solution containing 27.5% 
PEG3350, 0.2 M sodium nitrate, and 17.5% Glycerol. 
4.6.5 X-Ray Data Collection and Processing for CCL21 
X-ray diffraction data for CCL21 was collected at Argonne National Laboratory’s 
Advanced Photon Source (APS) using the SER-CAT 22-BM beamline. The data was processed 
using HKL2000134 and the CCP4 suite105 in order to solve the model structure and carry out 
refinements. Phaser Cell Content Analysis135 was utilized for determining the number of 
monomer copies contained within the asymmetric unit of the crystal, of which it predicted six. 
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Balbes214 taking the sequence of the previously solved NMR CCL21 structure (PDB ID: 2L4N) 
was able to provide an initial structure through the use of molecular replacement. The resulting 
solution only contained four copies within the asymmetric unit (Rwork=45% and Rfree=48%). The 
model created by Balbes was input into Refmac5107 for refinement. Taking the Refmac5 solution 
Parrot215 was then used in order to optimize the density. In order to improve the data further 
Buccaneer216 was used, giving it the inputs of the improved density from Parrot and the refined 
data from Refmac5. Then using CCP4’s Chainsaw utility the protein structure was pruned to 
remove all the flexible side chains found on the surface of the protein. In order to search for the 
additional copies that were missing from the initial output of Balbes the pruned structure from 
Chainsaw along with the output from Buccaneer were then input into Molrep.104 Molrep was 
able to find another additional copy to put that into asymmetric unit and this was run in Refmac5 
for further refinement. We repeated to use Molrep in order to find the final sixth copy that was 
predicted by Phaser Cell Content Analysis. After successfully finding the final copy Refmac5 
was again run on the output. Using our six monomer model further refinements were carried out 
in Coot106 in order to fill in the missing residues and rebuild the sections of the protein visually. 
Final refinements were carried out using Refmac5 and Phenix217 (Rwork=20.5% and Rfree=24.8%). 
4.6.6 X-Ray Data Collection and Processing of CCL19 
X-ray diffraction data for CCL19 was collected at Argonne National Laboratory’s 
Advanced Photon Source (APS) using the SER-CAT 22-BM beamline. The data was processed 
using iMOSFLM103 and Scala from the CCP4 software suite105 in order to integrate and scale the 
data. The output density was then input into Balbes215, along with the protein sequence, in order 
to generate a model structure for the protein. The resulting solution contained sixteen copies 
within the asymmetric unit (Rwork=42.9% and Rfree=47.1%). Taking the Balbes solution Parrot215 
85 
 
was then used in order to optimize the density. Additional copies were added to the model and fit 
into the density manually through visual refinement of the data using Coot.106 The output density 
and model from Coot was then input into Refmac5107 for additional refinement. Using the 
eighteen monomer model further refinements were carried out in Coot in order to fill in the 
missing residues and rebuild the sections of the protein visually. Final refinements were carried 
out using Refmac5 (Rwork=32% and Rfree=24%). 
4.6.7 NMR 2D 1H-15N HSQC Spectroscopy 
 All NMR spectroscopic data was collected at the NMR facility within the Medical 
College of Wisconsin on a Bruker Avance 600 mHz spectrometer equipped with a 1H/13C/15N 
cryoprobe. The identification of the sulfotyrosine binding sites located on CCL21 and 
determination of the effect sulfonation has on binding affinity was carried out by using 100 µM 
U-15N CCL21 dissolved in 25 mM MES (deuterated) pH 5.94, 0.02% NaN3, and 10% D2O in the 
NMR spectrometer. This was then titrated with slowly increasing concentrations of the fragment 
CCR7 peptides and monitored using the 2D NMR 15N-1H HSQC spectra, as previously 
described.137,218 The following molar ratios of U-15N CCL21 to N-terminal CCR7 fragment 
peptides were used: 1:0, 1:0.25, 1:0.5, 1:0.75, 1:1, 1:3, 1:7, and 1:10. The amide 1H-15N chemical 
shift perturbations (Δδ) were calculated using the formula: [(5ΔδH)2+(ΔδN)2]1/2, where ΔδH and 
ΔδN are the sum of all the changes in backbone amide 1H and 15N chemical shifts in ppm, 
respectively. The concentration dependent changes in chemical shift data once titrated with the 
assorted CCR7 N-terminal fragment peptides was implemented in the calculation of the 
dissociation constant (Kd) values by using a nonlinear fitting equation which factors in ligand 
depletion, as previously described.136,137 
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Note To Reader 4.1  
Members of the Volkman lab at the Medical College of Wisconsin performed the NMR 
described in this chapter. 
Note To Reader 4.2 
 Text and Figures were reprinted (adapted) with permission from Emmanuel W. 
Smith,5 Eric M. Lewandowski,5 Natasha A. Moussouras,3 Kyle G. Kroeck,5 Brian F. Volkman,3 
Christopher T. Veldkamp,1 and Yu Chen,5 Biochemistry 2016, Copyright of American Chemical 
Society 2016 
Note To Reader 4.3 
Text and Figures were reprinted (adapted) with permission from Andrew J. 
Phillips,1 Deni Taleski,2 Chad A. Koplinski,3 Anthony E. Getschman,3 Natasha A. 
Moussouras,4Amanda M. Richard,1 Francis C. Peterson,3 Michael B. Dwinell,4 Brian F. 
Volkman,3 Richard J. Payne,2 and Christopher T. Veldkamp,1 International Journal of Molecular 
Sciences 2017, Copyright by the authors 2017 
__________________________ 
5 Department of Molecular Medicine, University of South Florida, Tampa, Florida 33612, United 
States 
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Table 4.1 X-ray Data Collection and Refinement Statistics.   
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Structure 
 
M.W. 
 
Binding to CCL21 
 
 
BV15-012 
  
 
235.2 
 
 
+ 
 
 
BV15-015 
 
 
 
331.3 
 
 
+ 
 
 
BV15-017 
  
 
286.3 
 
 
+++ 
 
 
BV15-019 
  
 
192.2 
 
 
++ 
 
 
BV15-020 
  
 
238.2 
 
 
++ 
  
Compound 
Name 
Table 4.2 CCL21 NMR Titration Assay Hit Compounds. 
* + = Low mM Range Affinity, ++ = Mid mM Range Affinity, +++ = High mM Range Affinity 
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Figure 4.1. Superimposition of Truncated CCL21 with Truncated CCL19. The x-ray crystal 
structure of truncated CCL21 (purple, PDB ID: 5EKI) shows a highly similar N-loop conformation 
when compared to the structures of the related chemokines CCL19 (green) and CCL18 (orange, 
PDB ID: 4MHE). 
N-Loop 
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Figure 4.2. Chemokine Receptor Binding Mechanism. Chemokines follow a general two-
site/two-step mechanism of binding to their cognate receptor. (A) The chemokine and the target 
receptor’s flexible extracellular N-terminal domain enter within a proximal distance of each other. 
(B) The first step of the mechanism begins where the chemokine is recognized by the N-terminal 
domain of the receptor, with a large part of the affinity for this binding coming from the receptors 
sulfated tyrosine residues. (C) The second step of the mechanism begins when the flexible N-
terminal domain of the chemokine then gets internalized within the channel formed by the seven 
transmembrane domains of the chemokine receptor, where the tail binds. This results in the receptor 
initiating a downstream signaling cascade on the intracellular side of the membrane. 
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  A B 
C 
180˚ 
Figure 4.3. Truncated CCL21 (Residues 1-79) Crystal Structure. (A) The asymmetric unit of 
the CCL21 crystal which contains 6 monomeric copies of the protein. (B) Each monomer from the 
asymmetric unit superimposed onto chain B (monomer with the lowest average B-factor), showing 
that the variation between each copy of the monomer within the asymmetric unit is negligible. (C) 
Monomer B displayed from two sides and all the important secondary structure components 
labeled. 
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 
Figure 4.4. CCL21 Sulfotyrosine Recognition Site NMR Analysis. (A) Chemical shift 
perturbations in response to titration with the CCR7 fragment peptides plotted on graphs and 
mapped onto the CCL21 structure, with the statistically significant shifts shown in orange. The 
transparent orange surfaces on the CCL21 structures outline the binding pockets of the CCR7 
fragments. (B) Estimated binding affinities (Kd) and free energy contributions (∆G) for the binding 
of the corresponding CCR7 peptide fragments to CCL21 based on the NMR titration data.     
CCR7 5-11 (sY8) 
CCR7 5-11 (Y8) 
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CCL21 Residue CCL21 Residue 
B 
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Figure 4.5. Superimposition of CCL21 Crystal Structure with CCL21 NMR Structure.           
The x-ray crystal structure of truncated CCL21 (green) displays additional structural 
information about residues 71-77 when compared to the previously solved NMR structure 
ensemble of CCL21 (purple, PDB ID: 2L4N). This new information about the conformation of 
the C-terminal tail seen in the crystal structure shows it blocking a portion of the sulfotyrosine 
recognition site identified by the NMR titration experiments and points towards the N-loop.  
C-terminus 
N-Loop 
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Figure 4.6. Superimposition of CCL19 Crystal Structure with CCL19 NMR Structure.           
The x-ray crystal structure of truncated CCL19 (green) shows conformational variation in 
the N-loop when compared to the previously solved NMR structure ensemble of CCL19 due 
to the presence of the N-terminal tail (purple, PDB ID: 2MP1).  
N-Loop 
N-terminus 
C-terminus 
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Chapter 5: 
Summary 
 The focus of all three projects was using structure-based drug design in order to develop 
or improve small molecule inhibitors for the purpose of alleviating the various disease states that 
rely on the biochemical pathways being targeted. The first project sought to design novel dual 
activity inhibitors that bound to both the LpxA and LpxD proteins of Psuedomonas aeruginosa; 
where these enzymes are involved in the synthesis of Lipid A and are crucial to cell survival and 
viability of the bacterium. Through the use of molecular docking, complex crystal structure 
determination, and SPR assays, compounds that bind to both enzymes were able to be identified 
and serve as proof of concept for the central hypothesis of this project. Additionally, the crystal 
structures determined for LpxD displayed a novel structural mechanism for allosteric ligand 
inhibition that may lead to a greater understanding of the structure-function relationship of the 
enzyme and potentially more potent inhibitors. Future research for this project should seek to 
improve the affinity and specificity of the current lead compounds, as well as find additional lead 
compounds with unique scaffolds and chemotypes when compared to the previously identified 
small molecule inhibitors. It is also worth looking further into the novel mechanism of allosteric 
ligand inhibition and identifying how and why this effect is observed. This project would greatly 
benefit by gathering biochemical data to support the biophysical data observed in the SPR assay, 
as this would potentially offer further support of the current findings and possibly help lead to 
improved inhibitors with better binding affinities. 
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 The second project focused on determining why temocillin is ineffective in treating P. 
aeruginosa infections and elucidating the mechanism by which temocillin evades known 
mechanisms of antibacterial resistance in other infectious strains. By implementing fluorescence 
polarization assays, thermal shift assays, and determining complex crystal structures of 
temocillin and the parent compound ticarcillin with PBP3, the significant role the 6-α-methoxy 
group plays in destabilizing the temocillin-PBP3 complex structure was able to be determined to 
be the reason behind the inability of temocillin to treat P. aeruginosa infections. Furthermore, 
the blocking of Lys70 from being used as a catalytic base was determined to be the likely 
mechanism by which temocillin displays its ability to counter β-lactamase activity, as seen in the 
complex crystal structure between CTX-M-14 and temocillin. Future research for this project 
should look into the replacement of the 6-α-methoxy group on temocillin with other functional 
groups that would allow the compound to still counter β-lactamase activity while not 
destabilizing the PBP3-product complex, which would potentially allow the improved inhibitor 
to exhibit antibiotic properties against P. aeruginosa infections. 
 The third project aimed to determine crystal structures for the CCR7 binding chemokines, 
CCL19 and CCL21, and to utilize the sulfotyrosine recognition sites on the signaling proteins as 
hotspots for protein-protein interaction inhibitor design. By utilizing NMR perturbation assays 
and the crystal structure determined for CCL21, molecular docking experiments were carried out 
to identify lead compounds that targeted one of the sulfotyrosine recognition sites identified on 
the CCL21 protein. These compounds were confirmed to bind to the target through the use of 
additional NMR perturbation studies. The crystal structures determined for both CCL19 and 
CCL21 support the existence of two unique regulatory mechanisms for altering the signaling 
patterns exhibited by these proteins when binding to the CCR7 receptor. Future studies for this 
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project should seek to determine complex crystal structures of the lead compounds found 
through molecular docking studies to determine the exact interactions involved in the binding of 
the small molecules to CCL21. By understanding what specific interactions are involved in 
compound binding improvements to the affinities and specificities of the hit compounds can be 
made through alteration and addition of functional groups. Additional research should be carried 
out to identify the specific sulfotyrosine recognition sites found on CCL19 and then utilize this 
structural data for carrying out additional molecular docking studies that would identify novel 
inhibitors that target the protein-protein interface found on CCL19. Further research should also 
be carried out to determine if the C-terminal tail of CCL21 and the N-terminal tail of CCL19 
exhibit regulatory functionality over the binding of the chemokines to their cognate receptor 
through structural analyses. 
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